University of Windsor

Scholarship at UWindsor
Electronic Theses and Dissertations

Theses, Dissertations, and Major Papers

2011

The Role of Spy1 Protein Regulation In Breast Cancer
Mohammad Al Sorkhy
University of Windsor

Follow this and additional works at: https://scholar.uwindsor.ca/etd

Recommended Citation
Al Sorkhy, Mohammad, "The Role of Spy1 Protein Regulation In Breast Cancer" (2011). Electronic Theses
and Dissertations. 379.
https://scholar.uwindsor.ca/etd/379

This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor
students from 1954 forward. These documents are made available for personal study and research purposes only,
in accordance with the Canadian Copyright Act and the Creative Commons license—CC BY-NC-ND (Attribution,
Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the copyright holder
(original author), cannot be used for any commercial purposes, and may not be altered. Any other use would
require the permission of the copyright holder. Students may inquire about withdrawing their dissertation and/or
thesis from this database. For additional inquiries, please contact the repository administrator via email
(scholarship@uwindsor.ca) or by telephone at 519-253-3000ext. 3208.

The Role of Spy1 Protein regulation In Breast Cancer

By
Mohammad Al Sorkhy

A Dissertation
Submitted to the Faculty of Graduate Studies
through Biological Science
in Partial Fulfillment of the Requirements for 
the Degree of Doctor of Philosophy at the
University of Windsor



Windsor, Ontario, Canada
2010
© 2010 Mohammad Al Sorkhy



Declaration of Previous Publication
This thesis includes one original paper that has been previously published in peer
reviewed journals, as follows:
Thesis
Chapter
Chapter 2

Publication Citation

Publication status

Al Sorkhy, M., Craig R., Market B, Ard
R. and Porter L.

Published

I certify that I have permission from the copyright owner(s) to include the above
published material(s) in my thesis. I certify that the above material describes work
completed during my registration as graduate student at the University of Windsor.
I declare that, to the best of my knowledge, my thesis does not infringe upon
anyone’s copyright nor violate any proprietary rights and that any ideas, techniques,
quotations, or any other material from the work of other people included in my thesis,
published or otherwise, are fully acknowledged in accordance with the standard
referencing practices. Furthermore, to the extent that I have included copyrighted
material that surpasses the bounds of fair dealing within the meaning of the Canada
Copyright Act, I certify that I have permission from the copyright owner(s) to include
such material(s) in my thesis.

iii



Abstract
Cell growth and proliferation are tightly controlled by the cyclic regulation of the
cyclin dependent kinases (Cdks). Cdks are positively regulated through interactions with
regulatory Cyclin partners as well as being negatively regulated through interactions with
families of Cdk inhibitors (CKIs). The Spy1/RINGO family of proteins have emerged as
a unique class of ‘Cyclin-like’ proteins capable of directly binding both to the Cdks, as a
positive regulatory partner, as well as to at least one member of the CKI’s, p27Kip1, as a
negative regulator. Abnormally elevated levels of Spy1 promote cell proliferation, inhibit
apoptosis and are implicated in aggressive tumorgenesis in all cell/tissue types studied to
date. Understanding how Spy1 protein is regulated is essential in resolving how it
contributes to normal and abnormal growth processes. Herein, we demonstrate that Spy1
is degraded in a cell-cycle-dependent manner via the ubiquitin-proteasome system. We
have resolved the E3 ligase and essential phosphorylation sites mediating Spy1A
degradation. Furthermore, we show that Spy1 protein is stabilized in subsets of human
breast cancer samples. Using a stable mutant of Spy1 we demonstrate that this represents
an oncogenic modification in vitro and accelerates tumor formation in vivo. We further
show that these oncogenic properties are largely dependent upon the unique activation of
Cdk1 and the subsequent inhibition of the anti-apoptotic regulator FOXO1. Utilizing
Spy1 mutants unable to bind to the primary effectors p27 and Cdk2, we have found that
Spy1-mediated effects in the breast rely on direct interactions with each of these effectors
via separable functional mechanisms. This work reveals novel mechanisms regulating the
progression, and potentially the etiology, of human breast cancers and may be of
considerable therapeutic relevance.
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•

,WdZϮ͗ d,z>/EWEEd</E^d/sdKZ͕^Wzϭ͕/^dZ'd&KZ
'Zd/KEzd,h/Yhd/E>/'^Eϰ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϯϱ

•

/EdZKhd/KE ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϯϲ

•

yWZ/DEd>WZKhZ ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϯϴ

•

ĞůůƵůƚƵƌĞ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϯϴ

•

WůĂƐŵŝĚƐĂŶĚDƵƚĂŐĞŶĞƐŝƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϯϴ

•

/ŶŚŝďŝƚŽƌƐĂŶĚĂŶƚŝďŽĚŝĞƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϬ

•

dƌĂŶƐĨĞĐƚŝŽŶ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϭ

•

ĞůůƐǇŶĐŚƌŽŶŝǌĂƚŝŽŶĂŶĚĨůŽǁĐǇƚŽŵĞƚƌǇ͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϭ

•

/ŵŵƵŶŽďůŽƚƚŝŶ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϮ

•

/ŶǀŝǀŽůĂďĞůŝŶŐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϯ

•

/ŶǀŝǀŽƵďŝƋƵŝƚŝŶĂƚŝŽŶĂƐƐĂǇƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϯ

•

ƐŝZEŬŶŽĐŬĚŽǁŶĞǆƉĞƌŝŵĞŶƚ͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϯ

•

Z^h>d^͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϰ

•

^ƉǇϭWƌŽƚĞŝŶůĞǀĞůƐĂƌĞƌĞŐƵůĂƚĞĚŝŶĂĐĞůůĐǇĐůĞĚĞƉĞŶĚĞŶƚĨĂƐŚŝŽŶ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϰ

•

^ƉǇϭĚŐƌĂĚƚŝŽŶĚĞƉĞŶĚƐŽŶƉŚŽƐƉŚŽƌǇůĂƚŝŽŶǁŝƚŚĞŶEͲƚĞƌŵŝŶĂůƌĞŐŝŽŶ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϰϳ

•

^ƉǇϭƐƚĞĂĚǇƐƚĂƚĞůĞǀĞůƐĂƌĞƉƌŽƚĞĂƐŽŵĞĚĞƉĞŶĚĞŶƚ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϬ

•

dŚĞϯůŝŐĂƐĞƌĞŐƵůĂƚĞƐ^ƉǇϭĚĞŐƌĂĚƚŝŽŶ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϱϰ

•

ZĞƐŝĚƵĞƐdϭϱ͕^ϮϮ͕ĂŶĚdϯϯĂƌĞĞƐƐĞŶƚŝĂůĨŽƌ^ƉǇϭĚĞŐƌĂĚĂƚŝŽŶ͙͙͙͙͙͙͙͙͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϭ

•

/^h^^/KE ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϲϳ

•

Z&ZE^͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϬ

•

,WdZϯD/^Z'h>d/KEK&^Wz ϭWZKd/E>s>^ZWZ^EdEKEK'E/
>dZd/KE^͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϯ

•

/EdZKhd/KE ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϰ

•

DdZ/>EDd,K^͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϱ

•

ĞůůƵůƚƵƌĞ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϱ
ǀŝŝŝ



•

WůĂƐŵŝĚƐĂŶĚDƵƚĂŐĞŶĞƐŝƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϲ

•

ŶƚŝďŽĚŝĞƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϳ

•

dƌĂŶƐĨĞĐƚŝŽŶ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϳ

•

Ğůů^ǇŶĐŚƌŽŶŝǌĂƚŝŽŶĂŶĚĨůŽǁĐǇƚŽŵĞƚƌǇ͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϳ

•

/ŵŵƵŶŽďůŽƚƚŝŶŐ;/ͿĂŶĚ/ŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚŝŽŶ;/WͿ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϴ

•

YƵĂŶƚŝƚĂƚŝǀĞZĞĂůͬdŝŵĞdƌĂŶƐĐƌŝƉƚĂƐĞWZ;YͲZdͲWZͿ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϵ

•

<ŝŶĂƐĞĂƐƐĂǇƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϳϵ

•

>ƵĐŝĨƌĞĂƐĞĂƐƐĂǇ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϴϬ

•

^ŽĨƚŐĂƌĂƐƐĂǇ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϴϬ

•

&ŽĐƵƐĂƐƐĂǇ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϴϭ

•

&ĂƚWĂĚdƌĂŶƐƉůĂŶƚ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϴϭ

Z^h>d^͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϴϮ
•

^ƉǇϭWƌŽƚĞŝŶƐƚĂďŝůŝƚǇŝƐŝŵƉůŝĐĂƚĞĚŝŶŚƵŵĂŶďƌĞĂƐƚĐĂŶĐĞƌĐĞůůůŝŶĞƐ͙͙͙͙͙͙͙͙͙͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϴϮ

•

^ƉǇϭ^ƚĂďůĞƉƌŽƚĞŝŶŚĂƐŽŶĐŽŐĞŶŝĐƉƌŽƉĞƌƚŝĞƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϴϱ

•

^ƉǇϭ^ƚĂďůĞƉƌŽƚĞŝŶďŝŶĚƐĂŶĚĂĐƚŝǀĂƚĞƐĚŬϭƵŶŝƋƵĞůǇĚƵƌŝŶŐŵŝƚŽƐŝƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϵϭ

•

^ƉǇϭͲd^dŽŶĐŽŐĞŶŝĐĂĐƚŝǀŝƚǇŝƐĚĞƉĞŶĚĞŶƚƵƉŽŶĂĐƚŝǀĂƚŝŽŶŽĨĚŬϭ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϵϰ

•

ĚŬϭĂĐƚŝǀĂƚŝŽŶďǇ^ƉǇϭͲd^dŝŶŚŝďŝƚƐƚŚĞĂƉŽƉƚŽƚŝĐŵĞĚŝĂƚŽƌ&KyKϭ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϵϴ

•

^ƉǇϭ^ƚĂďůĞƉƌŽƚĞŝŶĂĐĐĞůĞƌĂƚĞƐƚƵŵŽƌĨŽƌŵĂƚŝŽŶŝŶǀŝǀŽ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϬϯ

•

/^h^^/KE ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϬϲ

•

Z&ZE^͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͘͘͘͘͘͘͘͘͘ϭϬϵ

•

,WdZϰ/Zd/EdZd/KE^t/d,W ϮϳE < ϮZ'h>d^^Wz ϭͲ /Eh
dhDKZ'E^/^͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϭϭ

•

/EdZKhd/KE ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϭϮ

•

Z^h>d^͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϭϱ

•

^ƉǇϭƉƌŽƚĞŝŶ>ĞǀĞůƐĂƌĞĞůĞǀĂƚĞĚŝŶŚƵŵĂŶƌĞĂƐƚĐĂŶĐĞƌƚŝƐƐƵĞƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϭϱ

•

ĞƚĞƌŵŝŶĂƚŝŽŶŽĨƚŚĞƉϮϳďŝŶĚŝŶŐƌĞŐŝŽŶǁŝƚŚŝŶ^ƉǇϭ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϭϴ

•

^ƉǇͲZϭϳϬĂŶĚͲϭϳϵĚŽŶŽƚďŝŶĚƚŽƉϮϳ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϮϭ

•

ĨĨĞĐƚŽĨ^ƉǇϭŵƵƚĂŶƚƐŽŶƉϮϳĚĞŐƌĂĚĂƚŝŽŶ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϮϰ

•

^ƉǇϭĚŝƌĞĐƚďŝŶĚŝŶŐƚŽďŽƚŚƉϮϳĂŶĚĐĚŬϮĂƌĞŝŵƉŽƌƚĂŶƚĨŽƌ^ƉǇͲŵĞĚŝĂƚĞĚ
ƚƵŵŽƌŐĞŶĞƐŝƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϮϴ
ŝǆ



•

DdZ/>EDd,K^͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϭ

•

ĞůůƵůƚƵƌĞ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϭ

•

WůĂƐŵŝĚƐĂŶĚDƵƚĂŐĞŶĞƐŝƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϭ

•

&ĂƚWĂĚƚƌĂŶƐƉůĂŶƚĂƚŝŽŶ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϮ

•

YƵĂŶƚŝƚĂƚŝǀĞZĞǀĞƌƐĞdƌĂŶƐĐƌŝƉƚĂƐĞWZ;YͲZdͲWZͿ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϮ

•

/ŵŵƵŶŽďůŽƚƚŝŶŐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϯ

•

dƌĂŶĨĞĐƚŝŽŶĂŶĚ/ŶĨĞĐƚŝŽŶƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϰ

•

ŶƚŝďŽĚŝĞƐ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϰ

•

WƵůƐĞŚĂƐĞ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϱ

•

dŝƐƐƵĞDŝĐƌŽĂƌƌĂǇ;dDͿŶĂůǇƐŝƐ͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϱ

•

/^h^^/KE ͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϲ

•

Z&ZE^͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϯϴ

•

,WdZϱ'EZ>/^h^^/KE͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϰϭ

•

ZĞĨĞƌĞŶĐĞƐ͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϰϴ

•

sŝƚĂƵĐƚŽƌŝƐ͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͙͘͘͘͘͘͘͘͘͘͘͘͘͘͘ϭϱϬ
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ͷǤ   ǥǥǥǤǥǥǥǥǥǥǥǥǥǤǤǥǤǥǤǤͷͻ
ǤȋȌǥǥǥǥǥǥǥǥǤǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǤǤǤͷͽ
Ǥ ǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǥǤǥǤǥǥǥǥǥǥǤǥǥǤǤǥǥǥͶ
ͺǤͷ ǥǥǥǥǥǥǥǥǥǥǥǥǥǤǤǥǥǥǤǥǥǥǤǥǥǥǥǥǤǤͼ
ʹ
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Introduction
The cell division cycle is a tightly orchestrated series of events designed to
coordinate DNA synthesis, cell growth and division into two daughter cells. Proper
movement through this cycle is the critical component regulating the growth and
development of all organisms. This seemingly straightforward cycle is cleverly designed
to detect any errors in this program and respond by halting cell growth or sending cells
into programmed cell death or apoptosis. Misregulation of the cycle in a manner that
eludes detection by this surveillance system has potentially devastating consequences for
the organism including the initiation of tumorigenesis, degenerative diseases or a host of
developmental disorders. Hence, how this cycle is regulated has been the focus of many
research groups for decades and elution of the key regulators represents some of the
greatest scientific advancements of our time.
Central Cell Cycle Events
Eukaryotic cells of all orders of complexity share a very similar cell division
cycle. The cycle is characterized by two major cellular events: the accurate duplication of
the genome in DNA synthesis, or S phase, and the separation of complete sets of
chromosomes into daughter cells in mitosis, or M phase. These pivotal events are
separated by two gap phases, G1 and G2 [1].
Terminally differentiated adult cells spend the majority of their time in G1 phase
where the cell increases in size through the coordination of a host of biosynthetic
activities and monitor the conditions of both the internal and external environment of the
cell to ensure that successful completion of both DNA synthesis and division are
possible. Based on environmental and developmental signals, cells in G1 may
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temporarily or permanently exit the cell cycle and enter quiescent or arrested phase
known as G0. During G0, cells are metabolically active and capable of performing many
functional roles, however they are unable to divide. If conditions are optimal, cells
proceed through to recruit initiator of replication proteins at specific sites called
replication origins forming the Replication Origin Complex (ORC). In eukaryotic cells,
assembly of Cell Division Cycle 6 (cdc6) with the ORC forms a pre-replicative complex
(pre-RC) which is required for loading of the Mini Chromosome Maintenance (MCM)
proteins onto DNA. The MCM proteins have helicase activity, essential in the unwinding
of the DNA to facilitate formation of the replication fork to allow primase and DNA
polymerase to begin replicating the lagging and leading strand respectively.
Following successful synthesis of DNA, or S-phase, the second gap phase occurs.
G2 is a much shorter phase of the cell cycle which plays an important role in ensuring
that the cell is capable of successful and error-free division. Entry into G2 activates
kinases which subsequently phosphorylate cdc6 to trigger disassembly of the ORC,
ensuring that synthesis of DNA occurs only once per cycle. The final phase of the cell
cycle, M phase, is composed of two major events: nuclear division (mitosis) and cell
division (cytokinesis). Mitosis is the process of distributing the duplicated chromosomes
into two nuclei. Following mitosis, the cell divides by cytokinesis to produce two
identical cells that will reenter the cycle at G1or G0 depending on the their environment
[1].
Regulation of the Cell Cycle
The correct course of successive cell cycle phases is ensured by the production
and destruction of proteins known as Cyclins. These proteins must bind to their catalytic
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subunit known as the Cyclin-dependent kinases (Cdks). Cdks are a group of
serine/threonine protein kinases that play an essential role in the regulation of eukaryotic
cell cycle division. The catalytic activity of Cdks is regulated by protein–protein
interactions,

post-translational

modification

of

Cdks

by

phosphorylation

or

dephosphorylation, and the binding of Cdk inhibitors (CKI) [2]. To initiate Cdk
activation, Cdks must be bound to their regulatory Cyclin partners that are synthesized
and degraded in a cell-cycle-dependent manner [3]. Following activation, these protein
complexes move cells through the stages of the cell cycle while constantly monitoring
DNA integrity and the nutrient/energy levels of the cell. Tight regulation of the cell cycle
is crucial for the health of cells and organisms and aberrant regulation of the Cyclin-Cdk
complexes are implicated in many different growth disorders [4].
Cyclin Regulation
Cyclins form a family of structurally and functionally similar proteins, now
encompassing 5 major families (A, B, C, D and E) [5]. Cyclins are characterized by the
regulation of their protein levels, which fluctuate throughout the different stages of the
cell cycle. All Cyclins share a conserved region of about 100 amino acids called the
Cyclin box, which binds to and activates Cdks [6] Most The primary Cyclins known to
regulate essential cell cycle movements ubiquitously in all mammalian somatic cells are
categorized into two main groups: the G1 Cyclins ( Cyclins C, D1 and E), which control
growth phase G1 and the G1/ S transition, and the so-called mitotic Cyclins ( Cyclins A
and B) which regulate the G2/ M transition and mitosis.
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Regulation of Cyclin-Dependent Kinases (Cdk)
Cyclin-dependent kinases (Cdks) are a group of serine/threonine protein kinases
that play an essential role in the regulation of eukaryotic cell cycle division. Up to date
there are eight Cdks have been characterized; however the most established regulators of
the somatic cell cycle are Cdk1, Cdk2, Cdk4 and Cdk6 [7]. Cdks are constitutively
expressed, but their catalytic activity is regulated by protein–protein interactions, and
both inhibitory and activating phosphorylation. When Cdks are found in their inactive
monomeric form, the conserved region of the kinase, known as the T loop, protects the
catalytic cleft and prevents the binding of substrates [8]. Upon Cyclin binding,
conformational changes in the Cdk cause the Cyclin Activating Kinase (CAK) to
phosphorylate a threonine residue (Thr161 in Cdk1, Thr160 in Cdk2) on the T loop. This
in turn exposes the catalytic cleft of the Cdk [8]. Cdk phosphorylation is not always
associated with activation. In fact, phosphorylation of two residues, Thr14 and Tyr15, by
kinases such as Wee1 and Myt1 inhibits Cdk activity. Thus, a Cdk must be
dephosphorylated by the phosphatase Cdc25 on Thr14 and Ty 15 to become fully active
[9].
Cyclin D1–Cdk4/6
In humans there are three closely related Cyclin D proteins Cyclin D1, Cyclin D2
and Cyclin D3. These proteins are expressed in an overlapping, semi-redundant fashion
in most proliferating cells and collectively regulate the progression of cells through the
cell cycle [10]. Transcriptional and translational regulation of CyclinD is controlled by a
number of mitogenic factors during G1 phase. Cyclin D is relocalized out of the nucleus
during S phase and the protein is degraded, through phosphorylation by GSK-3b [11].
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The Cyclin D–Cdk4/6 complex can be activated by CAK-mediated phosphorylation [12].
The principal known substrates of Cdk4 and Cdk6 are the retinoblastoma protein, pRb,
and other members of the pocket protein family. When these substrates are in their
hypophosphorylated forms, the E2F-facilited transcription of genes essential for DNA
synthesis is inhibited [4]. However, when phosphorylated by Cyclin D-Cdk4/6 this
initiates the earliest events for preparing cells to enter into S-phase of the cycle. In
addition, it is known that Cyclin-D-Cdk4/6 can bind and sequester the Cdk inhibitors,
p21 and p27, thereby providing an additional level of control over Cdk activity [12].
Hence, Cyclin D-Cdk4/6 plays a major role in moving cells through early-mid G1 phase
of the cell cycle.
Cyclin E–Cdk2
The next Cyclin to be expressed is Cyclin E in mid-G1 phase [13]. There are two
members of this family; Cyclin E1 and Cyclin E2, they are closely related and often coexpressed and referred as Cyclin E [14]. Cyclin E preferably binds and activates Cdk2,
which then phosphorylates a set of target proteins that facilitate the initiation of S phase
[15]. The Cyclin E-Cdk2 complex has been shown to phosphorylate S phase-specific
proteins such as NPAT (Nuclear-protein, atxia telagiectasia locus), which is involved in
the activation of histone gene transcription. Cyclin E-Cdk2 phosphorylates Rb family
proteins on different sites than Cyclin D-Cdk4-6. These phosphorylation sites are critical
for full inactivation of the Rb proteins, thereby initiating movement of cells into S-phase
of the cell cycle [16]. Another crucial task of the Cyclin E-Cdk2 complex is to
phosphorylate the Cdk inhibitor p27 and Cyclin E itself, targeting both of these critical
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proteins for degradation [17]. Cyclin E is regulated by ubiquitin-mediated degradation,
through the SCF (Skp1/Cullin/F box) family of ubiquitin ligases [14].
Cyclin A-Cdk2
Cyclin A is expressed after Cyclin E at the G1/S border, and also complexes with
Cdk2 [18]. There are two isoforms of the type-A Cyclins, A1 the embryonic form and A2
the somatic form [19]. The S phase transition and the regulation DNA replication are
dependent on the activity of Cyclin A-Cdk2. Cyclin A-Cdk2 phosphorylates Cdc6
following the initiation of replication, to trigger relocalization of the critical pre-RC
protein to prevent re-replication of DNA [20]. Cyclin A-Cdk2 has also been found to
phosphorylate Skp2 and Cdc20, two components of proteolytic pathways involved in
degrading proteins primarily in G1/S phase of the cell cycle progression, thereby playing
a key role in ensuring unidirectional movement of the cycle [21].
Cyclin B-Cdk1
There are three known B-type Cyclin family members; including Cyclin B1, B2
and B3. Each partner with and activate the G1/M Cdk, Cdk1. Cyclin B1 has been found
to be the main mitotic regulator in somatic cells of the three [22]. Although Cyclin B1 is
continuously shuttled between the cytoplasm and nucleus throughout interphase, Cyclin
B1 accumulates in the cytoplasm because the rate of its nuclear export exceeds its nuclear
import [23]. In somatic cells Cyclin B1 is expressed in late S and G2 phases, binding with
inactive Cdk1 in mid-G2. This complex is held in an inactive state through the stable
inhibitory phosphorylation of the Cdk1 subunit on Thr14 and Tyr15 by the Wee1 and
Myt1 kinases, which prevents premature initiation of mitosis [24]. At late G2, the Cdc25
phosphatase family remove the phosphates on Tyr15 and Thr14, prohibiting activation of
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the complex [25]. Entry into mitosis requires this active complex to relocalize quickly to
the nucleus. Neither Cyclin B1 nor Cdk1 has a strong Nuclear Localization Signal (NLS).
While Cyclin B1-Cdk1 can bind to importin β, the rate at which is it localized to the
nucleus does not describe the rapid accumulation at the onset of mitosis [26]. Pines and
Hunter suggested that Cyclin B1-Cdk1 complex associates with another protein that has a
functional NLS, such as Cdc25 or p21 [27]. The Donoghue group described a
relationship between Cyclin B1 and an ‘orphan’ Cyclin, Cyclin F which may represent a
binding relationship involved in the onset of mitosis [28].
Once in the nucleus, active Cyclin B-Cdk1 targets both structural proteins
involved in the execution of mitotic events, and regulatory proteins that are necessary for
the control and timing of these processes. A novel target of Cyclin B-Cdk1 is the
transcription factor FOXO1 (Fork head box O class proteins). The FOXO family of
proteins exhibit tumor suppressive functions through the transcriptional control of genes
involved in cell proliferation, apoptosis and oxidative stress [29]. Huang and others
showed that Cyclin B-Cdk1 phosphorylation of FOXO1 at Ser249 inhibits its
transcriptional activity. Hence demonstrating an additional role for Cyclin B1-Cdk1
complex in the regulation of cell fate decisions.
Cdk Inhibitors
Cdk inhibitors are divided into two categories differing in structure and function. The
INK4 (INhibitor of Cdk4) family of inhibitors, which includes p16INK4a (p16), p15INK4b
(p15), p18INK4c (p18) and p19INK4d (p19), specifically target Cyclin D-dependent kinases,
at least in part, by preventing Cyclin-Cdk assembly. The CIP/KIP (Cdk inhibiting
protein) family of inhibitors are composed of p21CIP1 (p21), p27KIP1 (p27) and p57KIP2.
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The latter are characterized by an N-terminal Cyclin–Cdk binding domain and a less well
conserved C-terminal domain with structural motifs that are suggestive of a role in
protein–protein interactions [30]. In contrast to the INK4 inhibitors which bind only the
Cdk subunit, the CIP/KIP inhibitors bind the Cyclin-Cdk complex targeting both Cyclin
D-Cdk4/6 complexes and Cyclin E/A–Cdk2 complexes. Structural studies of p27 binding
to Cyclin A-Cdk2 have demonstrated that p27 binds to the Cyclin-Cdk interface, with
part of the molecule contacting the ATP-binding lobe of the Cdk [12]. This in turn blocks
ATP binding and disrupts the conformation of the catalytic cleft, causing Cdk2 activity
inhibition. Concentrations of p27 that are sufficient for the inhibition of Cdk2 do not
necessarily inhibit Cyclin D1–Cdk4 [31]. Futhermore, a positive role in Cdk regulation
has also been suggested by data showing that p21 and p27 enhance the association of
Cyclin D-Cdk4 complex by stabilization it, and may facilitate the complex nuclear
localization [32]. Hence the CIP/KIP family members have differing activities when
bound to Cyclin E/A-Cdk2 and Cyclin D-Cdk4/6 and much more remains to be
discovered with regard to these specific activities and their physiological relevance.
p27
p27Kip1 plays a crucial role in regulating the response of cells to extracellular
signals such as low nutrient levels and contact inhibition and p27 plays a major role in
halting cell growth in conditions of cellular aging [33,34]. Although p27 mRNA levels
are generally constant throughout the cell cycle, p27 protein levels are under tight
translational control [35]. Proteolytic degradation is considered the most important
mechanism for regulating p27 levels. In this process, the p27 protein is marked for
degradation through a series of phosphorylation events [35]. One pathway leading to p27
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proteolytic degradation is mediated via phosphorylation on a C-terminal residue Thr187
by Cyclin-E-Cdk2 [36]. This phosphorylation occurs in late G1-early S phase and
facilitates the interaction of p27 with the Skp2-dependent E3 ligase complex, which
subsequently results in p27 degradation [35]. Recent data demonstrated that
phosphorylation of Tyr88 by oncogenic tyrosine kinases can facilitate Thr187
phosphorylation, leading to p27 degradation at the G1-S transition [37]. Upon cell cycle
entry, p27 is captured and sequestered by the Cyclin D-Cdk complex. This will decrease
the levels of active p27 to below threshold, thereby allowing the partial activation of
Cyclin E-Cdk2 complexes [38]. Consequently, the Cyclin E-Cdk2 complex facilitates its
own activation by phosphorylating Thr187 of p27, thereby initiating the degradation of
its inhibitor [17]. Some residual molecules of p27 remain bound to Cyclin D-Cdk
complexes throughout successive cycles and are only freed when growth factors are
removed from the environment. This results in the inhibition of Cyclin E-Cdk and the
arrest of the cell in G1 phase. Thus p27 uptake by Cyclin D-Cdk4 complexes can promote
the kinase activity of the Cyclin E-Cdk2 complex and help to establish the order of
activation [39].
Like many cell cycle regulatory proteins p27 is also regulated by cellular
localization. Phosphorylation of p27 on Ser10 by hKis kinase causes p27 cytoplasmic
localization [40], while its phosphorylation at Thr157 by Akt kinase has been shown to
impair its nuclear import; mutation of Thr157 to alanine resulted in an exclusively
nuclear p27 mutant [41].
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Role of p27 as a Tumor Suppressor
The function of p27 as a cell cycle regulator suggests that alterations in level
and/or localization could abrogate normal cell cycle progression. In fact several lines of
evidence suggest that p27 functions as a tumour suppressor; low p27 expression levels
have been recorded in many human cancers, including breast and colon cancers and are
correlated with a poor prognosis [42]. p27-null mice develop pituitary adenomas are
more susceptible to tumorigenesis in response to radiation and oncogenic retroviruses
[43,44]. Mutations in the gene encoding p27 are extremely rare and hence abnormal
regulation primarily occurs at the protein regulation and localization level. This is
supported by data in mouse models whereby mice lacking p27, or with a reduced p27
gene dosage, are more susceptible to tumorigenesis in response to radiation and
oncogenic retroviruses[45]. Reduction of p27 gene dosage also accelerates tumorigenesis
in mice lacking alleles of other tumor suppressors, including the retinoblastoma tumor
suppressor gene Rb and the phosphatase PTEN (a negative regulator of mitogenic
intracellular

signaling

through

PI3K)

[46].

p27

deficiency

also

accelerates

lymphomagenesis in Myc-overexpressing lymphoma models [43] and mammary
tumorigenesis in mice overexpressing ErbB2 [47]. Recent data has demonstrated a
relationship between p27 and ErbB2, a receptor frequently elevated in human breast
cancers, and p27 that may be important in the initiation or progression of breast cancer
[47]. It was noted that reduced p27 expression is correlated with ErbB2 overexpression,
at least in node-negative breast cancer and ErbB2 overexpression and activation reduce
p27 stability [48]. Furthermore, antibody-mediated inhibition of ErbB2 or treatment with
ErbB kinase inhibitors increases p27 levels and enhance its association with Cyclin E–
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Cdk2, leading to cell cycle arrest [49]. Similarly, overexpression of p27 in ErbB2overexpressing fibroblasts inhibits focus formation in vitro and tumor formation in vivo
[50]. Since a reduction in p27 expression also demonstrates resistance in vitro to
inhibitors targeted to ErbB receptors, breast cancers with low p27 levels may also
negatively respond to these therapies [51]. These data support an important therapeutic
relevance for monitoring p27 levels in breast cancer patients, as well as potentially
pointing to novel therapeutic strategies for subtypes of the disease.
Cell Cycle Checkpoints
Cellular systems possess control circuits which act as surveillance mechanisms to
monitor the completion of crucial cellular events and thereby regulate cell cycle
progression. There are two categories of checkpoint mechanisms: an intrinsic
surveillance system that operates throughout the cell cycle in order to ensure successive
events; and extrinsic mechanisms triggered by the detection of an error in the DNA, or
conditions of division, such as DNA damage, misregulation in DNA replication or DNA
assembly. Loss of any of these mechanisms reduces the fidelity of cellular events and
may lead to uncontrolled proliferation thereby contributing to tumorigenesis [52].
Of the checkpoint mechanisms known DNA damage checkpoints and spindle
checkpoints are among the most well studied, in part because of the clear link to human
disease. The DNA damage response is largely conserved in yeast and mammalian cells;
with the exception that mammalian cells are able to undergo apoptosis since the goal is
not the survival of a damaged cell but survival of the organism. The G1/S checkpoint
constitutes a primary regulator of the DNA damage response. Three genes associated
with this checkpoint are best described to mediate this response: ATM (ataxia
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telangiectasia mutated) [53], p53 and p21 [54]. At the G1/S checkpoint, cell cycle arrest
induced by DNA damage is p53-dependent. Usually, p53 levels are low, but DNA
damage can lead to rapid increase of p53 activity [55]. p53 stimulates the transcription of
different genes including p21 and Mdm2 [56]. The induction of p21, a CKI, results in
Cdk inhibition and cell cycle arrest by inhibiting the replication of damaged DNA [57] .
On the other hand, the ubiquitin ligase Mdm2 provides a crucial negative feedback loop
by promoting p53 degradation [58].
Different surveillance proteins recognize DNA damage and signal to primary
cascade of kinases to initiate the DNA damage signaling pathway; two of the initial
kinases activated are ATM, and Ataxia Telangiectasia and Rad3 Related (ATR). In
response to DNA damage, ATM/ATR phosphorylate p53 and the transducer kinase Chk2
which in turn further phosphorylates p53 at different sites to increase its transcriptional
activity, resulting in p21 blocking the cell cycle, at least at the G1/S checkpoint (Fig. 4)
[59]. G2 phase of the cell cycle is also capable of responding to the DNA damage signal;
in this phase cells are able to initiate a cell cycle arrest in the presence or absence of p53.
The entry into mitosis is prevented by maintaining Cdk1 in its inhibited form through
inactivating phosphorylation or by sequestration of components of the Cdk1- Cyclin B
complex [60]. This is achieved by the protein kinases Chk1 and Chk2, which are
activated upon DNA damage in an ATM-dependent manner that phosphorylate Cdc25
[61]. Phosphorylation of Cdc25 inhibits its activity and promotes its binding to 14-3-3
proteins, sequestering it outside the nucleus and preventing it from activating Cdk1Cyclin B and mitotic entry [62]. Figure 1 is a schematic diagram of some of the primary
regulators of cell cycle arrest upon DNA damage. Genes coding for p53 and ATM are

13

frequently mutated in human cancers suggests that the function of checkpoints is
important in cancer prevention [63] .

14

Figure 1. Schematic diagram showing the cellular response to DNA damage
damage.
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Posttranslational Modifications (Ubiquitination)
Protein ubiquitination is the main mechanism involved in the selective
degradation or processing of intracellular proteins in eukaryotic cells. In this process, the
addition of multiple ubiquitin molecules to a target protein is followed by its degradation
in a large protease complex, the 26S proteasome. The broad biological role of the
ubiquitin–proteasome proteolytic system (UPS) has been identified to encompass gene
expression, cellular stress response, antigen presentation, DNA repair, programmed cell
death, the cell cycle and tumorigenesis [64].
The covalent attachment of ubiquitin, a highly conserved 76-amino acid
polypeptide, to lysine residues of a substrate protein, is required for proteasomal
degradation. Protein ubiquitination involves a series of three classes of enzymes: the
ubiquitin-activating enzyme E1, the ubiquitin-conjugating enzyme Ubc or E2, and the
ubiquitin-protein ligase E3 (Figure 2). E1 first activates one ubiquitin molecule via the
formation of a high-energy thiol ester bond between the carboxyl-terminal glycine of
ubiquitin and the thiol group of a cysteine residue of E1. The ubiquitin is then transferred
to a cysteine residue on one of the E2 members. E2 enzymes may catalyze the attachment
of the single ubiquitin to a substrate protein directly, or transfer the ubiquitin to an E3
protein. The E3 enzyme can catalyse the formation of an isopeptide bond between the
carboxyl-terminal glycine of ubiquitin and the İ-amino group of lysine residues on a
target protein. The attachment of additional ubiquitin molecules by an E3 enzyme
eventually results in a multiply (poly) ubiquitinated substrate [65].
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Figure 2. The ubiquitin–proteasome system (UPS). Ubiquitin is first activated to a highenergy intermediate by E1. It is then transferred to a member of the E2 family
ofenzymes. From E2 it can be transferred directly to the substrate that is bound
specifically to a member of the ubiquitin ligase family of proteins, E3 (a). This occurs
when E3 belongs to the RING finger family of ligases. In the case of a HECT-domaincontaining ligase (b), the activated ubiquitin is transferred first to the E3 before it is
conjugated to the E3-bound substrate. Additional ubiquitin moieties are added
successively to the previously conjugated moiety to generate a polyubiquitin chain. The
polyubiquitinated substrate then binds to the 26S proteasome complex, where the
substrate is degraded to produce short peptides, and free and reusable ubiquitin is
released through the activity of de-ubiquitinating enzymes (DUBs). (Adapted from
Ciechanover A., and Ben-Saadon, [66]).
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Ubiquitin–Proteasome System in Cancer
A few studies have linked E2 to cancer, while E1 has never been characterized in
any tumor [67]. On the other hand, numerous reports have indicated that E3
misregulation often promotes cancer development. This usually results from the
stabilization of oncogenic products due to a malfunction of their E3 ligases, or the
accelerated turnover of tumor suppressor gene products due to overexpression of their
responsible E3 ligases [68]. Figure 3 represents a schematic of E3 oncogenic
involvement.
An example of E3 enzymes implicated in cancer is the human E6-associated
protein (E6AP). E6AP has been identified as a ubiquitin-protein ligase of the tumor
suppressor protein p53 in the presence of E6 oncoprotein from human papillomavirus
types 16 and 18 [69]. Polyubiquitinated p53 is then rapidly degraded by the 26S
proteasome, which may lead to tumorigenesis. Putative E3 proteins from various
organisms have been found to contain a conserved region, termed the Hect domain
(homologous to E6AP carboxyl-terminus), of approximately 350 amino acids
homologous to the carboxyl-terminus of E6AP [69].
Nedd4 ubiquitin-protein ligase is a member of the Hect-E3 protein ligase family.
Nedd4 contains an N-terminal calcium-dependent lipid binding domain (C2), a specific
protein–protein interaction domain (WW), and Hect domain in the C-terminal region
[70]. Reports have implicated Nedd4 and its yeast homologues Rsp5/Npi1/Pub1 in
multiple biological functions, including transcription and membrane transport [71].
Nedd4 has been found to be a proto-oncogene for PTEN, one example of the undeniable
biological significance of this class of proteins [72]. Table 1 summarizes the tumor
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associated E3 ligases and their substrates. Another example of the importance of the
ubiquitin system in cancer biology is highlighted by the regulation of the Cdk inhibitor
p27. As discussed previously, p27 is tightly regulated via ubiquitin mediated proteolysis.
Elevated levels of p27 have been found in Skp2-knockout mouse tissues and embryonic
fibroblast cells [45]. An increasing amount of evidence has shown that high expression
levels of Skp2 and Cks1 proteins are found in different human cancers, such as non-small
cell lung carcinomas [73]. Therefore, Skp2 and Cks1 are believed to play a pivotal role in
the degradation of p27 in human cancers. High levels of another E3 responsible for p27
degradation, Pirh2, are also found to be inversely correlated with p27 levels in human
head and neck cancers, as well as poor prognosis for these patients [74].
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Normal Status

Oncogenic status

Figure 3. Accumulation of oncogenic products and enhanced degradation of tumor
suppressor gene products in cancer cells. In normal cells, tumor suppressor gene products
negatively regulate transformation and cancerous growth while oncogene products are
quickly degraded by their E3 ligases. Thus E3 ligases which target oncogenes are known
as anti-oncogenic E3 ligases. Defects in the anti-oncogenic E3 ligase and overexpression
of the oncogenic E3 ligases, which target tumor suppressor gene products, often promote
carcinogenesis and cancerous growth (adapted from Kitagawa et al [68] ).
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Type

Example

Tumor- Associated substrates

HECT

Nedd4-1/2

TȕRI Smad2, 4, PTEN

Smurf

TȕRI Smad1, 2, 5, 7

WWP1

P63, TȕRI, Smad2, 4

Itch

P63, p73, Smad2

ARF-BP1(Huwe1)

P53

E6AP-E6

P53

Mdm2

P53, RB

COP1

P53

Pirh2

P53, p27

c-Cbl

EGFR

BRCA1

RPB8, RNAPII, ER

Arkadia

Smad7

TRIM32

Abi2

ȕTrCP

ȕ-catenin, IɤB, cdc25, Wee1, Period.

Skp2

P27, p57, p130, Tob1,c-Myc

Fbw7

c-Myc, c-Myb, CyclinE, c-Jun, Notch,

FBX4-ĮCrystallin

mTOR

Single RING

SCF

Cyclin D1

Cul4

Cdt2/PCNA

Cdt1, p21andRad23B

CSA
XPC

Table 1. Tumor-associated E3 ubiquitin ligases and their substrates. These ligases are
classified into five types: HECT-type, single RING-type, SCF-type, ECV-type, and Cul4base. Specific E3 ligases and their reported substrates, which are associated with cancer,
are also indicated. (Adapted from Kitagawa et al [68] )
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Speedy/RINGO Family Members
Xenopus Speedy (xSpy) was identified in a screen for genes that conveyed
resistance to a rad1 deficient strain of Schizosaccharomyces pombe when treated with
UV or gamma irradiation [75]. Shortly after, another group identified a structurally
identical protein that they called X-RINGO (Rapid INducer of G2/M progression in
Oocytes) [76]. Ectopic expression of xSpy1 in G2 arrested oocytes resulted in meiotic
maturation in the absence progesterone [75]. Down regulation of endogenous RINGO
caused a delay in oocyte maturation following induction with progesterone [76].
The human homolog of xSpy1/RINGO, Spy1, possesses 40% homology to the
Xenopus family member [77]. Six mammalian Spy1/RINGO family members have been
characterized to date [78]; Table 2 shows a full list of Speedy/RINGO family members
along with their tissue and species specificity. The originally characterized Spy1 is
Spy1A1, but will be referred to as Spy1 throughout this work. All family members share
a conserved core region known as the Speedy/RINGO box found to be crucial for Cdk
binding [78].
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Name

X-RINGO

Alternate

Tissue

Name

Expression

X-RINGO

A,

Species

X-RINGO

Xenopus

Oocyte

299

Cdc2/Cdk2

298

Cdc2/Cdk2

laevis
B,

Xenopus

Oocyte

laevis

Is27

Homo

Speedy/

Spy A 1,

Ubiquitous

RINGO A1

RINGO 3

(high

in sapiens/ Mus

testis)

musculus

Ubiquitous

Homo

Speedy/

Cdk Preference

(AA)

Is26
X-Spy 1

Length

Spy A2

RINGO A2

286/

Cdk2

283

313/

(high

in sapiens/ Mus

310/

testis)

musculus/ Sus

311

Cdc2/Cdk2

scrofa
Speedy/

RINGO 4

Testis only

RINGO 2

Testis,

Mus musculus

268

Cdc2

RINGO B
Speedy/
RINGO C

liver,

Cdc2/Cdk2

placenta,
bone marrow, Homo sapiens
kidney, small

293

intestine
Speedy/

RINGO 5

NA

Mus musculus

339

RINGO 1

NA

Homo sapiens

336

NA

RINGO D
Speedy/

Cdc2/Cdk2/Cdk5

RINGO E

Table 2. Members of the Speedy/RINGO family. Known Spy1/RINGO family members
with their tissue and species specificity and preferred binding partners indicated.
Modified from Gastwirt [79].
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Spy1 Regulation of the Mammalian Cell Cycle
In mammalian cells, overexpression of Spy1 has been shown to increase cell
proliferation and reduce the G1 phase population in comparison to control cells [77]. The
acceleration of cell proliferation caused by Spy1 overexpression is dependent on Cdk2
activation, while knockdown of endogenous Spy1 using siRNA caused a significant
reduction in Cdk2 kinase activity and subsequent increase in cell number [77]. These
results support that Spy1 is an essential protein in cell proliferation. Interestingly, Spy1
was also found to bind to the cell cycle regulator p27 in vivo and in vitro, and to colocalize to the nucleus with p27 [80]. Although Spy1 functions like a Cyclin, it was found
to bind to the Cdk binding site of p27 rather than the Cyclin binding site. Furthermore,
Spy1 was found to enhance cell growth and proliferation in a p27-dependent manner
[80]. Interestingly, Spy1-Cdk2 complex was shown to phosphorylate p27 at Thr187
leading to its proteasomal degradation and enhanced cell cycle progression [81]. To date,
Spy1 binding and activation of Cdk2 and enhanced p27 degradation is the accepted
model by which Spy1 promotes cell proliferation and overcomes p27-mediated cell cycle
arrest.
The Role of Spy1 in the DNA Damage Response
In response to DNA damage, cells activate checkpoints to inhibit cell cycle
progression and allow DNA damage repair, or program themselves to undergo cell death
(apoptosis). As described in more detail above, different mechanisms are in place to
ensure that Cdk activity is precisely controlled upon DNA damage, including
Chk1/Chk2-mediated phosphorylation and degradation of Cdc25 phosphatases, and
p53-mediated Cdk inhibition by p21 transcription [82].
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Overexpression of Spy1 was demonstrated to prevent Cdk inhibition, cell cycle
arrest and promote cell survival following treatment of genotoxic substances, such as
cisplatin and camptothecin [83]. It was later demonstrated that these effects are due to the
inhibition of apoptosis rather than an increase in cell proliferation [84]. To examine the
role of Spy1 in ultraviolet-induced apoptosis, cells overexpressing Spy1 were exposed to
different doses of UV radiation in comparison to mock cells. Cells overexpressing Spy1
displayed less sensitivity to DNA damage and expressed fewer apoptotic markers such as
AnnexinV and caspase activation, these results were found to be p53 and Cdk2 dependent
[85].
Mechanistically, inhibition of Cdk2 by small molecule inhibitors or by siRNA
has been shown to activate checkpoint signaling leading to Chk1 feedback, and activating
the specific checkpoint [86]. These results demonstrate the importance of Cdk2 inhibition
in checkpoint activation upon DNA damage. Thus, full activation of Cdk2 may
negatively affect checkpoint activation. Spy1 overexpression results in inhibition of Chk1
activating phosphorylations, and also prevents phosphorylation of both the single strand
binding protein RPA and the Histone variant H2A.X [84]. Cells expressing a Cdk2 nonbinding mutant of Spy1 fail to demonstrate these effects on checkpoint signaling,
demonstrating the essentiality of Spy1-Cdk2 interaction in this phenomenon [84]. Figure
4 shows a proposed model of the effect of Spy1 activation of Cdk2 on the DNA damage
response.
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Figure 4. Proposed role of Spy1/RINGO in regulation of DNA damage responses. An
overall perspective is presented on the role of Spy/RINGO in regulating CDKs in
response to DNA damage and thereby affecting cell cycle progression and apoptosis.
(adapted from Gastwirt et al. [79])
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The Role of Human Spy1 in Tumorigenesis and Normal Mammary Gland
Development.
The initial evidence linking Spy1 to breast cancer came from a SAGE analysis
study by Zucchi and colleagues in 2004, where they found Spy1 is among 50 genes
upregulated in breast ductal carcinoma [87]. Following this, Golipour et al performed a
comprehensive study showing the role of Spy1 in mammary gland development and
tumor formation [88]. Spy1 protein and RNA levels are tightly regulated during the
development of the mammary gland [88]. Spy1 levels were elevated in the proliferating
virgin gland and remained elevated in early stages of pregnancy. By late pregnancy, Spy1
levels dropped dramatically, coincident with terminal differentiation of the gland.
Utilizing the BALB/c mouse cell line (HC11) Spy1 exhibited abrogated cellular
morphology and failed to form the proper acini in cell culture. Moreover, Spy1overexpressing HC11 cells were able to accelerate tumor formation when transplanted
into the cleared fat pads of BALB/c mice. Glands transplanted with HC11-Spy1
developed visible tumors before 14 weeks post surgery while control glands were unable
to form tumors in the same time interval. This study clearly indicates that Spy1 protein
may have the ability to accelerate tumor formation and may play a potential role in
cancer initiation [88] . Shortly after, Qing and colleagues found high levels of Spy1 in
hepatocellular carcinoma (HCC) [89]. It was also found that Spy1 was overexpressed in
HCC samples as compared with the adjacent normal tissue. They also were able to
correlate high levels of Spy1 with a poor prognosis for hepatocellular carcinoma patients
[89].
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Collectively, these studies along with the known roles of the primary effectors of Spy1,
Cdk2 and p27, in carcinogenesis clearly indicate that Spy1 plays a major role in cancer
development and/or initiation, and paves the way for further investigation of the possible
roles of Spy1 in tumorigenesis.
Hypothesis and Objectives
This research aims to elucidate how Spy1 protein is regulated and modified
throughout the cell cycle as well as to investigate the possible role of Spy1 protein levels
in breast cancer initiation and progression. Our working hypothesis is that: misregulation
of the Spy1 protein is a critical event in the initiation of breast cancer and thus the
promotion of Spy1 degradation will represent a novel and specific therapeutic strategy in
the treatment of breast cancer.
This hypothesis will be tested through the following objectives:
•

To elucidate the molecular mechanisms controlling Spy1 regulation throughout
the cell cycle.

•

To determine the functional significance of Spy1 degradation in normal and
abnormal growth conditions.

•

To elucidate the importance of the Spy1-p27 interaction for cell cycle
progression.

The results from these questions will provide critical information with regard to the
regulation of a novel cell cycle regulator. Future work may provide promise toward the
development of novel drug targets and/or biomarkers in the treatment and detection of
breast cancer.
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Chapter 2
The Cyclin-Dependent Kinase activator, Spy1A, is
Targted for Degradation by the Ubiquitin Ligase
NEDD4
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Introduction
Members of the Speedy/RINGO family are unique cyclin-like regulators of the cell
division cycle. There are now four members characterized in mammals exhibiting distinct
tissue expression patterns and functional specificity [1]. The originally characterized
family member Spy1A1, herein referred to as Spy1A, is expressed constitutively in most
human tissues; it shortens the G1/S transition through activation of CDK2 and is essential
for cell proliferation to occur [2]. Activation of CDKs by Spy1/RINGO proteins is
thought to occur in an atypical fashion, independent of cyclin binding and in the absence
of CDK phosphorylation within the T-loop [3]. Spy1A can also act in a unique fashion to
prevent inhibition of CDK2 by p27Kip1 (p27), this occurs through direct interactions with
the p27 protein and results in enhanced degradation of p27 [4,5]. At a cellular level
Spy1A also plays a role in the DNA damage response, functioning to enhance cell
survival and promote cell proliferation in lieu of apoptosis [6,7]. Our lab and others have
demonstrated that Spy1A is capable of promoting precocious development and
tumorigenesis in the mammary gland and that Spy1A protein levels are implicated in
invasive ductal carcinoma of the breast [8,9]. Hence, determining how Spy1A protein
levels are regulated may reveal novel information regarding the dynamics of cell cycle
control during normal and abnormal growth conditions.
In mammals, Spy1A mRNA is known to be up-regulated during G1/S; however
regulation at the protein level has not been studied [2]. The Xenopus homologue of
Spy1A, X-Spy1, has been shown to undergo steps of proteasome dependent processing
and degradation in a manner dependent on the initiation and progression of meiotic
events [10]. Degradation of X-Spy1 occurs following meiosis I and is mediated by the
ubiquitin ligase Siah-2, this depends on phosphorylation of X-Spy1 on a carboxy terminal
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residue S243 [10]. Cyclin proteins in general are tightly regulated temporally and
spatially through the cell cycle, controlled on a fundamental level by the ubiquitinproteasome system (UPS). The UPS is the primary mechanism involved in the selective
degradation of intracellular and membrane-bound proteins, and aberrations in this
critically important system are correlated to many diseases including cancer [11,12].
Ubiquitination involves the conjugation of ubiquitin to a substrate protein via a concerted
effort from three classes of enzymes: the ubiquitin-activating enzyme E1, the ubiquitinconjugating enzyme E2, and the ubiquitin-protein ligase E3 [13]. The E3 enzyme
catalyzes the formation of a chain of ubiquitin molecules which then targets the substrate
protein for degradation by the 26S proteasome [12,14,15]. Given the functional cyclinlike properties of Spy1A it is a valid hypothesis that Spy1A may also be subject to a cell
cycle dependent ubiquitin-mediated proteolysis, however whether the mammalian
somatic cell cycle regulates this critical protein in the same manner as that seen during
oocyte maturation in Xenopus warrants investigation.
Herein we demonstrate that Spy1A is ubiquitinated and degraded during G2/M
phase of the cell cycle. We have determined 3 key amino acids within the N-terminal
region of Spy1A which are essential to support regulated degradation of the protein and
we have demonstrated that the C-terminal region, known to regulate X-Spy1 degradation,
is dispensable for degradation of the mammalian homologue. We have resolved that the
E3

ligase

Neuronal-Precursor-Cell-Expressed

Developmentally

Downregulated-4

(Nedd4) is capable of binding to Spy1A, and that dominant negative forms and
knockdown of Nedd4 reduce ubiquitination and subsequent degradation of Spy1A.
Furthermore, we show that non-degradable forms of Spy1A do not trigger intrinsic cell
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cycle checkpoints but rather promote cell proliferation; demonstration that this
mechanism may contribute to tumorigenesis.
Experimental procedures
Cell Culture - Human mammary breast cancer cells, MCF7 (ATCC) and human
embryonic kidney cells, HEK293 (293; ATCC), were maintained in DMEM medium
(Sigma) containing 2mM L-glutamine (Sigma), penicillin and streptomycin (Invitrogen),
and were cultured in a 5% CO2 environment. MCF7 cells were supplemented with 10%
(vol/vol) fetal calf serum (Sigma) and 293 cells were supplemented with 10% fetal
bovine serum.
Plasmids and Mutagenesis - The Nedd4-PCEP plasmid (Nedd4), dominant negative
Nedd4-PCEP plasmid (Nedd4DN) and empty vector control (PCEP) were provided by Dr.
Dale S. Haines (Temple University School of Medicine). HA-Ubiquitin (HA-Ub) was
provided by Dr. Sylvain Meloche (Université de Montréal). Creation of Myc-Spy1APCS3 vector was described previously (Porter et al 2002). QuikChange Multi-SiteDirected Mutagenesis (SDM; Stratagene) was used to incorporate new silent sites into the
original Spy1-pJT0013 vector [2] in order to facilitate the cloning of deletion mutants A
(DMA), B (DMB), C (DMC), G (DMG) and Z (DMZ). A BglII site was inserted by
altering

nucleotide

256

from

T

to

C

using

the

primers

GACGATTTAATTCAAGATCTCTTGTGGATGGACTGCTGC-3’

and

#A043

5’-

#A044

5’-

GCAGCAGTCCATCCACAAGAGATCTTGAATTAAATCGTC-3’ to construct the
pRA01 vector. Using the pRA01 plasmid a Mlu site was also added by altering
nucleotide

175

from

C

to

G

using

CAACAAATCTAAACGCGTCAAAGGACCTTGTCTGG-3’

and

#A004
#A005

5’5’-
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CCAGACAAGGTCCTTTGACGCGTTTAGATTTGTTG-3’ to make the vector pRA02.
The pRS2 vector was constructed from Spy1-pJT0013 by creating an NdeI site just after
the

stop

codon

using

the

primers

#A045

5’-

and

#A046

5’-

GTCTTGTGTCCATATGTGTTTTGTGGTGACCC-3’
GGGTCACCACAAAACACATATGGACACAAGAC-3’.

The

pRS1

vector

was

constructed by creating a MluI site in the Spy1-pJT0013 plasmid by altering nucleotide
nucleotide

175

from

C

to

G

using

CAACAAATCTAAACGCGTCAAAGGACCTTGTCTGG-3’

primers

#A004

5’-

and

#A005

5’-

CCAGACAAGGTCCTTTGACGCGTTTAGATTTGTTG-3’. DMA was created by
digesting wild-type Spy1A (in pRS1) with NdeI and MluI in order to remove the first 57
amino acids of the protein. DMB was created by digesting wild-type Spy1A (in pRA02)
with MluI and BglII in order to remove 27 amino acids. DMC was created by digesting
wild-type Spy1A (in pRA01) with BglII and NcoI in order to remove 61 amino acids.
DMG was created by digesting wild-type Spy1A (in pJT0013) with NcoI and BbsI in
order to remove 94 amino acids. Finally, DMZ was created by digesting wild-type Spy1A
(in pRS1) with BbsI and NdeI in order to remove the last 47 amino acids. Gel
electrophoresis of these digestions was run on a 1% agarose gel; the desired band was
excised and gel-extracted (Bio Basics) for ligation using T4 DNA ligase (Fermentas). For
all five deletion mutants, linkers containing a silent restriction site, PstI, and
complementary sticky ends were designed, commercially synthesized (Sigma), annealed
and utilized in the ligations. In each case, 20 µL ligation reactions were carried out at
22°C for 2-4 hrs. containing a 1:3 vector to linker ratio. Ligations were transformed into
DH5Į cells and selected for ampicillin resistance, mini-prepped, and digested with PstI
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(Fermentas) to detect the correct ligation. The five Spy1A deletion mutants (depicted in
Fig. 3A), spanning the length of the gene, were moved from the pJT0013 into pCS3 using
EcoRI and XbaI sites flanking the gene.
SDM was also carried out using the PCS3 vector to generate the Spy1A-T15A,
Spy1A-T33A, Spy1A-S22A and Spy1A-S247A mutants. Spy1A-T15A was designed
using

the

primers

#A151

5’-

GAGACACCACCTACTGTCGCTGTTTATGTAAAATCAG-3’

and

#A152

5’-

CTGATTTTACATAAACAGCGACAGTAGGTGGTGTCTC-3’;

Spy1A-T33A

was

designed

using

the

primers

#A-153

5’-

CAGCCTAAAAAGCCCATTGCACTGAAGCGTCCTATTTG-3’

and

#A154

5’-

CAAATAGGACGCTTCAGTGCAATGGGCTTTTTAGGCTG-3’; Spy1A-S22A was
designed

using

the

primers

#A139

TAGATCACATCAGC-3’

5’-GTTTATGTAAAATCAGGGGCCAA

and

#A140

CTGATGTGATCTATTGGCCCCTGATTTTACATAAAC-3;
designed

using

the

primers

Spy1A-S247A
#A143

GGATTGTCTTCATCATCAGCGTTATCCAGTCATACTGCAGGGGTG-3’

5’was
5’and

#A144 5’- CACCCCTGCAGTATGACTGGATAACGCTGATGATGAAGACAATCC3’. Successful cloning in all cases was determined by DNA sequencing (Robarts
Sequencing Facility; Univ. of Western Ontario).
Inhibitors and Antibodies - The following antibodies were used: Spy1A (NB 100-2521;
Novus), Nedd4 (ab14592; Abcam), Myc (9E10 and C19; Santa Cruz), HA (Y11 and F7;
Santa Cruz), Actin (MAB1501R; Chemicon), Cyclin E (551157; BD Pharmingen), IgG
(SC66186; Santa Cruz). The following inhibitors were used: N-Acetyl-L-leucyl-L-leucyl-
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L-norleucinal N-Acetyl-Leu-Leu-Norleu-al (LLNL; Sigma A6060); MG132 (Sigma
C2211); Cyclohexamide (Sigma C7698); nocodazole (Sigma M1404) , thymidine (Sigma
T1895) and Lactacystin (Boston Biochem I-116).
Transfections - Calcium phosphate precipitation transfections were carried using 10
µg of DNA per 10 cm tissue culture plate. 250 µL CaCl2 was incubated with the DNA for
30 sec., 250µL 2x BBS at pH 7.01 was added while vortexing and the solution was
incubated for 10 min. The mixture was added slowly to the cells and then incubated in
3% CO2 for 12-16 hrs. Media was then changed and plates were returned to 5% CO2 for
at least 12 hrs. prior to harvest.
Cell Synchronization and Flow Cytometry - 293 cells were synchronized using double
thymidine block. Briefly, cells were cultured in media containing 2 mM thymidine for 16
hrs., followed by release into normal media for 8 hrs. and then a second thymidine block
for 14 hrs., and then released into media containing 70 ng/ml nocodazole (with or without
10 µM MG132 as indicated). MCF7 cells were synchronized by being cultured in a
serum-free media for 48 hrs., followed by release into media containing serum and 70
ng/ml nocodazole. 293 and MCF7 cells were trypsinized at specified times, washed twice
in PBS, and then either used immediately or fixed and stored at -20°C. Fixation was
carried out by resuspending cells at 2 x 106 cells in 1 mL of PBS, followed by slow
addition of an equal amount of 100% ethanol. Within 1 week, fixed cells were pelleted,
washed, and resuspended in 300 µL of PBS. Samples were then prepared for flow
cytometry by treating with 1 µL of 10 mg/mL stock of DNase free RNase (Sigma) and 50
µL of 500 mg/mL propidium iodide stock solution. Data was collected using a Beckman
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Coulter FC500 (Biology Dept.; U of Windsor) and cell cycle profiles were analyzed
using CPX Beckman Coulter FC500 software.
Immunoblotting - Cells were lysed in 0.1% NP-40 lysis buffer (0.1% NP-40, 1M Tris
pH 7.5, 0.5M EDTA, 5M NaCl) containing protease inhibitors (PMSF 100 µg/mL,
aprotinin 5µg/mL, leupeptin 2µg/mL) for 30 min on ice. Bradford Reagent was used to
determine the protein concentration following the manufacturer’s instructions (Sigma).
Aliquots of lysates containing 20-30 ȝg protein were subjected to electrophoresis on
denaturing SDS-10% polyacrylamide gels and transferred to Polyvinylidene FluoridePlus transfer membranes (Osmonics Inc.) for 2 hrs. at 30V using a wet transfer method.
Blots were blocked for 2 hrs. in TBST containing 3% non-fat dry milk (blocker) at room
temperature. Primary antibodies were reconstituted in blocker and incubated over night at
4°C at a 1:1000 dilution for all antibodies, and secondary antibodies were used at a
1:10,000 dilution in blocker for 1 hr at room temperature. Blots were washed three times
with TBST following incubation with both the primary and secondary antibodies. Washes
were 6 min each following the primary antibody and 10 min each following the
secondary antibody.

Chemilumiminescent Peroxidase Substrate

was

used

for

visualization following the manufacturer’s instructions (Pierce). Chemiluminescence was
quantified on an Alpha Innotech HD2 (Fisher) using AlphaEase FC software.
Immunoprecipitation reactions were carried out using equal amounts of protein
(~200ȝg/mL) incubated with 2 ȝg of primary antisera, as indicated, overnight at 4°C. This
was followed by the addition of protein A–Sepharose (Sigma) and incubated at 4°C with
gentle rotation for an additional 2 hrs. Complexes were washed extensively with 0.1%
NP-40 lysis buffer and resolved by 10% SDS-PAGE.
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In Vivo Labeling - 293 cells were treated with 10µM MG132 and 70 ng/ml nocadozol
for 14 hrs. followed by incubation in phosphate-free media for 2 hrs. and cells were
labeled with [32P]orthophosphate (0.3 mCi/ml) (PerkinElmer) for 4 h at 37°C. Cells were
lysed and immunoprecipitated with Myc antisera. Immunoprecipitations were washed
rigorously with TBST and samples were analyzed by 10% SDS page gel. Gels transferred
to PVDF membranes were visualized using a Cyclone phosphoimager and quantified
using OptiQuant software (Perkin Elmer; Biology Dept.; U of Windsor).
In Vivo Ubiquitination Assays - 293 cells were plated and transfected appropriately in
a 100-mm dish. 24 hrs. after transfection cells were treated with 10 µM MG132 for 14
hrs. Cells were then collected, pelleted by centrifugation, lysed in 200 µl of preboiled
lysis buffer [50 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 1% SDS, and 1 mM DTT], and
further boiled for an additional 10 min. Lysates were clarified by centrifugation at 13,000
rpm on a microcentrifuge for 10 min. Supernatant was diluted 10 times with 0.5% NP40
buffer and immunoprecipitated with anti-Myc antibody. Immunoprecipitates were washed
3 times and resolved by 10% SDS-PAGE, followed by immunoblotting with anti-HA
antibody.
siRNA Knockdown Experiments – siRNA against Nedd4-1 was synthesized by
inserting the oligo 5’GATGAAGCCACCATGTATA into the pSUPER-basic vector, as
previously described [16]. As a control, LacZ siRNA (siCntl) was synthesized and
inserted into pSUPER-basic vector as described (21). 293 cells were transfected using 12
µg of either Neddd4 siRNA or siCntl per 100 mm tissue culture plate and total protein
was isolated from cell cultures and resolved using 12% SDS polyacrylamide gels as
described above.
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Results
Spy1A protein levels are regulated in a cell cycle dependent fashion.
MCF7 and 293 cells were blocked in G1 using serum starvation and thymidine block
procedures respectively. Cells were released into serum and nocodozole containing media
and populations enriched in G1 or G2/M phases of the cell cycle were collected as
determined by flow cytometry analysis (Fig. 1A and C). Cell lysates from the respective
populations were immunoblotted for endogenous Spy1A expression (Fig. 1B & D; upper
panels). Cyclin E was utilized as a control for the cell cycle stage (Fig. 1B; middle panel),
and Actin was used as the loading control (Fig. 1B and D; lower panels). These data
demonstrate that Spy1A protein levels are greatly decreased during G2/M phase of the
cell cycle and support that, like many important cell cycle proteins, Spy1A is tightly
regulated in a cell cycle dependent fashion.
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FIGURE 1. Spy1A protein levels are regulated in a cell cycle dependent fashion. (A)
Upper panel; Flow cytometry profiles for MCF7 cells either untreated (Cntl), collected
immediately following release from serum starvation (G1) or collected 16 hrs. following
release into nocodozole containing media. Lower panel; Percentage of cells in each phase
of the cell cycle as determined by flow cytometry analysis software. (B) Cell lysates from
each population described in A were immunoblotted with α-Spy1A, α-Cyclin E and αActin. (C) Upper panel; Flow cytometry profiles for 293 cells either untreated (Cntl),
blocked by double thymidine block (G1) or blocked and then released into media
containing serum and nocodazole (G2). Lower panel; Percentage of cells in each phase of
the cell cycle as determined by flow cytometry analysis software. (D) Cell lysates from
each population described in C were immunoblotted with α-Spy1A and α-Actin.
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Spy1A degradation depends on phosphorylation within the N-terminal region.
Using a panel of Spy1A deletion mutants (Fig. 2A), we began to narrow down the region
within the Spy1A protein that was necessary for degradation. We first determined
whether deletion of any of the regions of Spy1A would result in stabilization of the
protein. 293 cells were transfected with wild-type Spy1A or deleted versions of the
Spy1A protein, DMA-DMZ. Cells were synchronized at G2/M and levels of Spy1A were
monitored by immunoblotting (Fig. 2B; upper left panel). All deletion mutants of Spy1A
were degraded by G2/M phase with the exception of the mutant lacking the first 57 amino
acids (DMA). Asynchronous cells demonstrate that all deletion mutants were expressed
(Fig. 2B; upper right panel). Collectively, these data demonstrate that the N-terminal
region of Spy1A is essential to mediate degradation of the protein and that unlike the
Xenopus homolog of Spy1 the C-terminal region is dispensable for degradation.
Phosphorylation is often the key event regulating recognition of the substrate
protein by the E3 [11]. To determine whether deletion of the N-terminal region of Spy1A
altered the phosphorylation status of the protein, orthophosphate labeling was performed
on G2 populations of cells expressing either wild-type or Spy1A deleted of its N-terminal
region (DMA) in the presence of MG132. Over 3 experiments a significant decrease in
the incorporation of orthophosphate was repeatedly observed when the N-terminal region
of Spy1A was deleted (Fig. 2C). From this information, we conclude that there is at least
one phosphorylation site present within the N-terminal region of Spy1A that may play a
significant role in regulating Spy1A stability.
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FIGURE 2. Spy1A degradation relies on the N-terminal region. (A) A schematic diagram
for the different Spy1A deletion mutants is depicted and restriction sites used for
cleavage of the region are indicated. (B) 293 cells were transfected with Myc-Spy1APCS3 (wt) or the different deletion mutant DMA-DMZ (A-Z). Transfected cells were
treated with nocodazole (left hand panels; synchronous) or no treatment (lower panel;
asynchronous) for 16 hrs. post transfection. Lysates were immunoblotted with α-Myc or
α-Actin. (C) 293 cells were transfected with Myc-Spy1A-PCS3 (wt) or deletion mutant A
(DMA). 12 hrs post-transfection cells were treated with nocodazole and MG132 for 14
hrs. followed by orthophosphoric acid
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P for an additional 4 hrs. Cells were lysed,

immunoprecipitated with α-Myc and imaged on a Cyclone phosphorimager (upper blot).
Immunoblot for α-Myc was used as a control (lower blot). Incorporation of orthophosphate was quantified using OptiQuant software; right panel represents results of one
representative experiment of 3.
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Spy1A steady state levels are proteasome dependent.
After determining the timing of Spy1A degradation during cell cycle progression, we set
out to investigate the mechanism by which this occurs. To determine whether this
mechanism was proteasome dependent we studied 293 cells in the presence or absence of
the proteasome inhibitors MG132, Lactacystin and the calpain inhibitor LLNL. Spy1A
protein levels were significantly elevated in the presence of MG132 as well as
Lactacystin but not in the presence of the calpain inhibitor or the vehicle controls (Fig.
3A; upper panel; ETOH – vehicle for LLNL, DMSO – vehicle for MG132 and
Lactacystin). This data implicates that Spy1A abundance is proteasome dependent. 293
cells were then utilized for an in vivo ubiquitination assay where cells were transiently
transfected with HA-tagged ubiquitin (HA-Ub) and Myc-tagged Spy1A (Myc-Spy1A) in
the presence of MG132 followed by immunoprecipitation with α-Myc (Fig. 3B; lower
panel). Immunoblotting with α-HA revealed that Spy1A was labeled with HA-ubiquitin
in vivo (Fig. 3B; upper panel). The experiment was then repeated using endogenous
Spy1A and immunoprecipitation with α-HA. Immunoblotting with α-Spy1A revealed
that Spy1A was indeed labeled with HA-ubiquitin in vivo (Fig. 3C; upper panel).
Collectively these results demonstrate that Spy1 protein levels are regulated via the UPS.
To determine whether the stability shown by DMA is due to lack of ubiquitination 293
cells were utilized in an in vivo ubiquitination assay. Cells were transiently transfected
with HA-tagged Ubiquitin (HA-Ub) and either Myc-tagged Spy1A (Myc-Spy1A), DMA
or DMB in the presence of MG132 followed by immunoprecipitation with α-Myc (Fig
3D; lower panel) Immunoblotting with α-HA revealed that Spy1A and TMB were
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labeled with HA-ubiquitin in vivo, whereas TMA was not. This result demonstrates that
lack of ubiquitination is responsible for the stability of the N-terminal deletion of Spy1A.
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FIGURE 3. Spy1A steady state levels are proteosome dependent. (A) Cells were treated
for 14 hrs with a calpain inhibitor (LLNL; 25µM) or proteasome inhibitors (MG132;
10µM and Lactacystin; 10µM ) as well as the relevant vehicle control for LLNL (ETOH)
and MG132 and lactacystin (DMSO). Lysates were analyzed by immunoblotting with αSpy1A and α-Actin. (B) 293 cells were transfected with HA ubiquitin (HA-Ub), MycSpy1A-PCS3 (Myc-Spy1A) and PCS3 empty vector (Myc-Cntl), 12 hr. post-transfection
10µM MG132 was added for 14hr. α-Myc immunoprecipitations were immunoblotted
with α-HA and α-Myc. (C). 293 cells were transfected with HA Ubiquitin (HA-Ub), or
empty vector control (PMT123), 12 hr. post-transfection 10µM MG132 was added for
14hr. α-HA immunoprecipitations were immunoblotted with α-Spy1A and α-IgG-mouse.
(D) 293 cells were transfected with HA ubiquitin (HA-Ub), Myc-Spy1A, PCS3 empty
vector, PMT123 empty vector, Spy1A-deletion mutant A (DMA) and Spy1A deletion
mutant B (DMB) 12 hr. post-transfection 10µM MG132 was added for 14hr. α-Myc
immunoprecipitations were immunoblotted with α-HA and α-Myc
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The E3 ligase Nedd4 regulates Spy1A degradation.
There are many different E3 ubiquitin ligase enzymes that are able to function in the
ubiquitination pathway. To determine which E3 ligase functions in the degradation of
Spy1A a protein blast for the N-terminal region of Spy1A revealed a weak potential
interaction region for WW domain containing proteins, PPxxxxY spanning from P11Y17 in the Spy1A sequence. Immunoprecipitation with endogenous Spy1A followed by
coomassie staining revealed a predominant band enriched in G2 populations of cells at
approximately 110-115 kD (data not shown). It is known that the 114 kD WW domaincontaining ligase Nedd4 (product of neuronal precursor cell-expressed developmentally
down-regulated gene 4), while preferring the canonical PPxY sequence, also binds to a
variety of proline rich regions with phosphorylated threonine or serine residues to trigger
ubiquitination and subsequent degradation [15,17,18]. Due to this we investigated the
potential role of Nedd4 in Spy1A degradation. Interestingly, Nedd4 is a family of
conserved E3 ubiquitin ligases found to function as both proto-oncogenes as well as
tumor suppressors. Nedd4 is known to both mono-, di- and poly-ubiquitinate its target
proteins, where polyubiquitinated proteins are selectively targeted for degradation by the
proteosome (21). Clarifying the biology of the Nedd4 family and relevant substrates may
provide important information for tumorigenesis [19-23]. Co-immunoprecipitation of
lysates overexpressing exogenous Nedd4 as well as Myc-Spy1A in the presence of
MG132 demonstrates that Nedd4 interacts with Spy1A in vivo (Fig. 4A). These results
were then confirmed by using endogenous binding in two different cell lines 293 and
NIH3T3 (Fig. 4B). To further investigate whether Nedd4 is functioning as an ubiquitin
ligase for Spy1A, we repeated the co-immunoprecipitation experiment using
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overexpression of wild-type Nedd4 or dominant negative Nedd4 (Nedd4DN) in the
presence of HA-Ub. Nedd4DN contains a single amino acid substitution which prevents
the formation of a thioester bond with ubiquitin and hence renders Nedd4 inactive
[12,14,15]. Immunoblotting for Spy1A, followed by quantification, revealed that HA-Ub
incorporation was significantly decreased in the presence of Nedd4DN (Fig. 4C). To
further establish whether Nedd4-1 was required for both binding and degradation of
Spy1A, 293 cells were transfected with either siNedd4 or an siRNA control (siLacZ;
siCntl) followed by immunoblotting with α-Nedd4 (Fig. 4D upper panel), α-Spy1A (Fig.
4D Middle Panel) and α-actin (Fig. 4D lower panel). Densitometry of detected bands
demonstrates that Spy1A protein levels are accumulating when Nedd4 levels are reduced
with siRNA. To examine the effect of knockdown of Nedd4-1 on the binding interaction
between Spy1A and Nedd4, 293 lysates overexpressing Myc-Spy1A and either siNedd4
or siCntl were immunoprecipitated with α-Myc (Fig. 4E lower panel). Immunoblotting
with α-Nedd4 shows that Nedd4-Spy1 binding was significantly reduced following
knockdown of Nedd4-1 (Fig. 4E upper panel) To assess the effect of Nedd4 on
endogenous Spy1A, Nedd4 was transfected into 293 cells in the presence and absence of
MG132, and endogenous levels of Spy1A were measured. Overall Spy1A protein levels
were consistently decreased in 2 separate experiments by at least 20% when Nedd4 was
transiently transfected in the absence of MG132 as compared to when MG132 was
present (Fig. 4F). To confirm the effect of Nedd4DN on Spy1 protein stability, Nedd4DN,
Nedd4 and Myc Spy1A were transfected into 293 cells. 12 hrs. post-transfection cells
were released, at 16 hrs post-transfection 50 µg/ml cycloheximide was added to prevent
de novo protein synthesis. Over 3 separate experiments immonoblotting for Spy1A,
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followed by quantification, showed that Spy1A stability was decreased in the presence of
Nedd4 but was in fact significantly more stable in the cells transfected with Nedd4DN
(Fig. 4G). Collectively, this data demonstrates a novel relationship between two proteins
previously implicated in tumorigenesis; Spy1A and Nedd4.
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FIGURE 4. The E3 ligase Nedd4 regulates degradation of Spy1A. (A) 293 cells were
transfected with empty vectors (PCS3 or PCEP), Nedd4-PCEP (Nedd4) or Myc-Spy1APCS3 (Myc-Spy1A) and treated with MG132 for 14 hrs prior to harvest. α-Myc
immunoprecipitations were immunoblotted with α-Nedd4 (upper panel) and α-Myc
(lower panel). Lysates from NIH3T3 cells served as positive control for Nedd4
expression (+; lane 5). (B) 293 and NIH3T3 cells were treated with 10µM MG132 for 14
hr., lysates were immunoprecipitated with α-Nedd4 or α-IgG and immunoblotted with αSpy1A (upper panel) or α-IgG (lower panel). (C) 293 cells were transfected with empty
vectors (PMT123 or PCEP), Nedd4-PCEP (Nedd4), HA Ub-PMT123 (HA-Ub) or
Nedd4-PCEP Dominant Negative (Nedd4DN) and treated with MG132 for 14 hrs. prior to
harvest. α-HA immunoprecipitations were analyzed by immunoblotting for α-Spy1A
(upper panel) and α-HA (middle panel). Lysates were used to demonstrate
Nedd4/Nedd4DN transfection (lower blot). Densitometry of Ha-Ub-Spy1A was performed
and equalized using α-HA blot (right hand panel). This is one representative experiment
of 3. (D) 293 cells were transfected with siRNA against Nedd4 (siNedd4) or siRNA
against LacZ (siCntl). Lysates were immunoblotted with α-Nedd4 (upper blot), α-Spy1A
(middle blot) and α-Actin (lower blot). Densitometry of Spy1 levels was performed and
equalized to the Actin loading control (right hand panel). This is one representative
experiment of 3. (E) 293 cells were cotransfected with Myc-Spy1A and either siNedd4 or
siCntl, 12 hr. post-transfection 10µM MG132 was added for 14hr. α-Myc
immunoprecipitations were immunoblotted with α- Nedd4 (upper panel) or for α-Myc
(lower panel). (F) 293 cells were transfected with PCEP empty vector control (lane 1)
and Nedd4-PCEP (Nedd4; lanes 2 & 3). Cells were either treated with MG132 (lane 2) or
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DMSO (lanes 1 & 3). Lysates were immunoblotted with α-Spy1A and α-Actin.
Densitometry for Spy1A levels was carried out and is depicted after equalization with
Actin levels (right hand panel). One representative experiment of two. (G) 293 cells were
transfected with Myc-Spy1A-PCS3 (Myc-Spy1A) along with either PCEP empty vector
(Cntl), Nedd4-PCEP (Nedd4) and, Nedd4-PCEP Dominant Negative (Nedd4DN). 16 hrs.
after transfection cyclohexamide was added and cells were collected at 30, 75 and 120
min. time points. Cell lysates were analyzed by immunoblotting for α-myc antibody.
Actin was used as a loading control (lower panel). Densitometry over 3 separate
experiments is demonstrated in the lower panel. Error bars represent SEM ** = p<0.001.
(H) 293 cells were transfected with Myc-Spy1A-PCS3 (Myc-Spy1A) along with either
sicontrol (siCntl), Nedd4-PCEP (Nedd4) and siNedd4. 16 h after transfection
cyclohexamide was added, and cells were collected at 30-, 75-, and 120-min time points.
Cell lysates were analyzed by immunoblotting for Į-Myc antibody. Actin was used as a
loading control (lower panel). Lower panels (G and H) represent densitometry where
Spy1A expression is equalized with actin over three separate experiments. Error bars
represent S.E. Statistics reflect Nedd4, Nedd4DN, or siNedd4 transfections as compared
with control transfections at each time point. *, p < 0.05; **, p < 0.01.
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Residues T15, S22, and T33 are essential for Spy1A degradation.
Cell cycle regulatory proteins which are targeted to the UPS rely on signal transduction
mechanisms to control the timing of this essential event. We have demonstrated that the
N-terminal region of Spy1A is essential for mediating degradation. Hence, we focused on
elucidating essential sites within this region that may target the protein for degradation.
Utilizing the NetPhos 2.0 Server tool residues T15, S22, and T33 were isolated as
potential phosphorylation sites [24]. Site-directed mutagenesis was performed to alter
Spy1A residues T15, S22, and T33 to non-phosphorylatable alanines. Additionally we
generated a similar mutation at S247 in the C-terminal region to serve as a control. 293
cells were transfected with the relevant constructs prior to synchronization at G2/M.
Surprisingly, mutation of all of T15, S22, and T33 to a non-phosphorylatable alanine
prevented degradation and ubiquitination of Spy1A (Figs. 5A & B). Blotting
asynchronous cell populations revealed that protein expression was not affected (Fig. 5A;
right panel) and flow cytometry analysis demonstrated that effects at T15, S22 and T33
were not due to a failure of the mutant Spy1 expressing cells to properly arrest in G2
phase (Fig. 5E; upper panel). This suggests that phosphorylation, or maintenance of
charge of all three of T15, S22, and T33 is essential in regulating the turnover of Spy1A.
To further assess the effect of these mutations on Spy1A degradation, 293 cells were
transfected and then treated with 50 µg/ml cyclohexamide 16hrs. post-transfection.
Immunoblotting for Spy1A showed that cells transfected with the mutants have stabilized
Spy1A levels (Fig. 5C). Quantifying 3 separate experiments demonstrate that indeed all 3
mutations significantly enhance the stability of Spy1A protein (Fig. 5C; right hand
panel). To assess whether these sites are phosphorylated in vivo a triple mutant (Spy1A-
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TST) was created where all 3 elucidated sites were mutated to a nonphosphorylatable
alanine (T15A, S22A and T33A). Phosphorylation of Spy1A-TST at G2/M was
compared to that of wt-Spy1A using an orthophosphate labeling experiment. A
significant decrease in phosphorylation was observed with the triple mutant (Fig. 5D),
demonstrating that Spy1A is phosphorylated at residues T15, S22 and T33 during G2
phase of the cell cycle. Importantly, these mutations provide us with a valuable tool to
assess the essentiality of Spy1A degradation on cell cycle dynamics.
Aberrant Spy1A degradation enhances cell proliferation but does not trigger a cell
cycle arrest. Cyclin protein levels serve as a monitoring mechanism for the cell to ensure
that each phase of the cell cycle is complete before the next is initiated; such checkpoint
mechanisms are essential in protecting the integrity of the cell. The Spy1/RINGO family
members have been functionally characterized as novel cyclin-like proteins; hence we
utilized the Spy1 degradation mutants in order to determine whether progression of the
somatic cell cycle requires the timely degradation of Spy1A. Cells from figure 5A which
were overexpressing Spy1-wt, Spy1-T15A, Spy1-T33A, Spy1-S22A or Spy1-S247A
were analyzed via flow cytometry analysis (Fig. 5E). Wild-type and mutant Spy1A
constructs revealed very similar cell cycle profiles (Fig. 5E asynchronous cells; lower
panel), demonstrating that prevention of Spy1A degradation in this cell type does not
trigger a cell cycle arrest.
To test the effects of ablating Spy1A degradation on cell proliferation live and
dead cell populations were monitored by trypan blue analysis. Spy1A and mutant
constructs significantly enhance cell proliferation as compared to mock with p values of
0.01 for mock:WT, 0.001 for mock:Spy1A-T15A, 0.0004 for mock:Spy1A-T33A, and
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0.001 for mock:Spy1A-S22A (these stats are not reflected in Fig. 5F). There was no
statistical change in the number of dead cells from one transfection to another (Fig. 5F;
grey bars). Interestingly, Spy1 degradation mutants statistically enhanced proliferation
over Spy1A alone by 20-60% (Fig. 5F; black columns). p-values for these comparisons
were 0.009 for WT:Spy1A-T15A, 0.002 for WT:Spy1A-T33A and 0.03 for WT:Spy1AS22A.
Collectively, these data demonstrate that residues T15, S22, and T33 within the
N-terminal region of Spy1A are important phosphorylation sites for mediating the
degradation of the protein. Furthermore, preventing degradation of Spy1A does not
trigger cell cycle arrest but rather results in enhanced cell proliferation; hence
representing a mechanism which may contribute to tumorigenesis.
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FIGURE 5. Phosphorylation on T15, T33 and S22 is needed for Spy1A degradation. 293
cells were transfected with Spy1A wild-type (wt), Spy1A-T15A (T15A), Spy1A-T33A
(T33A), Spy1A-S22A (S22A) or Spy1-S247A (S247A). (A) Cell lysates were treated
with nocadazole (G2 population; left panels) or untreated (Asynchronous population;
right panel). Half of the population was kept for flow cytometry analysis (Fig. 5D). The
remainder were lysed and immunoblotted with α-Myc for Spy1A (upper panels) and αActin (lower panels). (B) All samples were co-transfected with HA-Ub followed by
treatment with MG132 for 14 hrs. Lysates were immunoprecipitated with α-Myc and
immunoblotted for α-HA (upper panel) or α-Myc (lower panel). (C) 16 hrs. after
transfection cyclohexamide was added, cells were collected at 30, 75 and 120 min. time
points. Cell lysates were immunoblotted with α-Myc. Actin was used as a loading control
(lower panel). Spy1 bands were quantified using densitometry and values corrected for
using Actin. Relative densitometry over 3 separate experiments. Error bars represent
SEM ** = p<0.001 (D) 293 cells were transfected with Myc-Spy1A-PCS3 (wt) or the
triple mutant Spy1A-TST. 16 hrs post-transfection cells were treated with nocodazole and
MG132 for 14 hrs. followed by orthophosphoric acid

32

P for an additional 4 hrs. Cells

were lysed, immunoprecipitated with α-Myc and imaged on a Cyclone phosphorimager
(upper blot). Immunoblot for α-Myc was used as a control (lower blot). Incorporation of
ortho-phosphate was quantified using OptiQuant software, right panel represents results
of one representative experiment of 2. (E) Cells from (A) were analyzed by flow
cytometry. CPX analysis was carried out to determine the % of cells in each population
and are depicted above the schematic of the cell cycle profiles. (F) Alive and dead cells
were counted at 36 hrs. post-transfection using trypan blue exclusion. Error bars reflect
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standard deviation between 3 separate transfections and a standard T-test was performed
assuming equal variance. Statistical data shown reflects comparisons between the wt
transfected cells and mutant transfected cells * p≤ 0.05, ** p≤ 0.01.
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Discussion
Importance of Spy1A degradation in cell cycle regulation. Tight regulation over the
protein levels of cyclins and activity of their respective kinase is known to be one
mechanism by which the cell ensures the proper timing of cell cycle events [25]. More
recently it has come to light that CDKs can also be activated by members of the
Speedy/RINGO family. These proteins lack any sequence homology with cyclins
however our data demonstrates that, like the cyclins, Spy1A is tightly regulated at the
protein level through the cell cycle. The importance of Speedy/RINGO proteins in the
cell cycle is irrefutable, expression of Spy1A is essential for cells to progress through
DNA synthesis, overexpression enhances cell proliferation and deregulated levels lead to
aberrant growth [5,8] [9]. In immortalized cells our results demonstrate that nondegradable mutants of Spy1A do not trigger a cell cycle arrest but rather promote
significantly enhanced proliferation over Spy1 wild-type expression alone. Whether
preventing degradation results in Spy1 activation of unique CDKs, and whether this
contributes toward the proliferative phenotype of these mutants remains to be determined.
Most importantly, these data support the possibility that altered degradation of the Spy1A
protein is an unchecked cell cycle event which contributes toward proliferation and may
play a mechanistic role in human tumorigenesis.
The Spy1A degradation mechanism. Herein, we demonstrate a novel interaction
between Spy1A and the E3 ligase Nedd4 which mediates the degradation of Spy1A. This
demonstrates that in addition to functional differences, the mammalian Spy1A isoform is
subject to differential protein regulation as compared to its Xenopus counterpart [10]. The
domain structure of Nedd4 family members are very similar and contain a series of
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typically two to four WW domains which function as recognition sites for specific
substrates or adaptor proteins [26,27]. The WW domains of Nedd4 preferentially
recognize PPxY motifs in their substrates [28]. The N-terminal region of Spy1A lacks
this consensus site; however is known that Nedd4 can also interact with phosphorylated
threonine or serine residues to trigger ubiquitination and subsequent degradation [15]
[18]. Notably all deletion mutant constructs for Spy1A, depicted in figure 2A, were found
to interact with Nedd4 in vivo (data not shown). This suggests that the Nedd4-Spy1A
interaction relies on at least 2 separate binding regions in the Spy1A protein; resolution of
these required binding regions remain to be determined. Following mutagenesis of 3
potential phosphorylation sites within the N-terminal region of Spy1A, we have
determined that preservation of amino acids 15-33 is generally important for Spy1A
degradation. T15 is completely conserved among the mammalian Spy1A homologues,
and is preceded by a highly conserved proline rich region (PPTV); whether these sites are
involved in proteolysis of other Spy1/RINGO family members remains to be determined.
Furthermore, the Nedd4 family consists of nine members, all containing WW domains.
We know from overexpression assays using Nedd4-1 cDNA that this member of the
Nedd4 family is capable of interacting and promoting the ubiquitination and degradation
of Spy1A. Additionally, specific knockdown of Nedd4-1 prevented the degradation of
Spy1 and interactions between Spy1-Nedd-4, collectively these data strongly support that
Nedd4-1 is the specific isoform mediating Spy1 degradation. Whether other members of
the Nedd4 family are also capable of regulating the degradation of Spy1A is currently not
known. It is known that the Nedd4 family are capable of also mono- and diubiquitinating their substrate proteins. While we can not rule out that these modifications
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also occur, our data demonstrate that Spy1A can be polyubiquitinated by Nedd4 and that
this targets the protein for degradation.
Spy1A-Nedd4 interaction in cancer. From the current catalogue of known Nedd4
substrates it appears that Nedd4 can act as both a proto-oncogene, as well as a tumor
suppressor under different circumstances. For example, Nedd4 has been shown to
mediate the degradation of the vascular endothelial growth factor receptor 2 (VEGF-R2)
[19]. VEGF-R2 is a positive regulator of cell proliferation, migration, and angiogenesis
[29], and it is known to be up-regulated in colon [30], brain [31], and breast cancer [32].
In addition, Nedd4 has been shown to lead to the down-regulation of the insulin-like
growth factor 1 receptor (IGF-1R) [20], which has been implicated in both the initiation
and development of many human cancers types [33]. Our data provides further evidence
that Nedd4 can function like a tumor suppressor to regulate the levels of proteins
stimulating cell growth mechanisms. Conversely, Nedd4, or Nedd4 family members,
have been shown to regulate the degradation and function of important tumor suppressor
genes such as the phosphatase and tensin homolog 1 (PTEN), p53 and the p53 family
member, p73 [21-23]. This novel interaction between the Spy1/RINGO family and
Nedd4 strengthens the possibility that Nedd4 substrate specificity may contribute to
oncogenesis, thereby allowing for the accumulation of proliferative proteins such as
Spy1A. Further resolving how this mechanism is functioning in human cancers is an
important direction that may provide a novel direction in the design of cancer
therapeutics.
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Chapter 3
Misregulation of Spy1 Protein levels represent an
oncogenic alterations
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Introduction
The Speedy/RINGO family of proteins are novel regulators of the cell division
cycle, capable of activating the cyclin-dependent kinases (Cdks) independent of cyclin
binding and phosphorylation within the Cdk T-loop [1]. In Xenopus oocytes, the
Speedy/RINGO family member X-Spy1 was shown to prematurely activate Cdk2, and to
allow progression through the G2/M checkpoint via activation of the MAPK pathway,
thus promoting rapid oocyte maturation [2]. The human Speedy/RINGO homologue,
herein referred to as Spy1, is constitutively expressed in most human tissues and is
essential for somatic cell cycle progression [3]. Ectopic expression of Spy1 subsequently
promotes rapid cell cycle progression through a shortened G1/S phase that is attributed, at
least in part, to the activation of Cdk2 [3]. Furthermore, Spy1 can prevent the inhibitory
affects of the tumor suppressor p27Kip1 on Cdk2 by directly promoting p27 degradation,
suggesting yet another mechanism by which Spy1 can enhance both normal and aberrant
cell growth [4-6]. Spy1 also plays a role in the DNA damage response, functioning to
promote cell survival and override protective barriers in the presence of damaged DNA
[7,8]. Collectively, these data support a role for Spy1 in promoting carcinogenesis.
Indeed, SAGE analysis has shown that Spy1 is expressed at elevated levels in one case of
invasive ductal carcinoma of the breast, Spy1 protein levels have also been implicated as
a prognostic marker in hepatic carcinogenesis and ectopic overexpression of Spy1 can
accelerate mammary tumorigenesis in vivo [9-11]. Hence, how Spy1 levels are regulated
and how this contributes to the initiation and/or progression of tumorigenesis is of high
priority for understanding both normal and abnormal cell growth programs.
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Spy1 protein levels are tightly regulated during the cell cycle, being degraded via
ubiquitin mediated proteolysis utilizing at least two separate mechanisms [12,13]. We
have resolved three residues within the N-terminal region of the protein, T15, S22, and
T33, essential for targeting Spy1 for Nedd4-mediated degradation in G2/M phase of the
cell cycle [12]. Mutation of these residues generates a non-degradable form of Spy1
(Spy1-TST) which was found to significantly enhance cell proliferation over that of wildtype Spy1 [12]. Herein, we demonstrate that elevated levels of Spy1 protein are
implicated in subsets of human breast cancer cell lines. Utilizing the nondegradable
mutant of Spy1 we show that that altering Spy1 protein stability or expressing very high
levels of Spy1-WT protein is a transforming event. Interestingly, preventing Spy1 protein
degradation results in an enhanced activation of Cdk1 kinase activity during mitosis and
subsequent inhibition of the pro-apoptotic regulator FOXO1. Collectively this data
supports a unique relationship between the stabilization of Spy1 protein and mammary
tumorigenesis.
Materials and Methods
Cell Culture
The mouse embryonic fibroblast cell line NIH 3T3 (NIH), human embryonic kidney cell
line HEK 293 (293) and HTB 231 were purchased from ATCC and maintained in
DMEM medium (Sigma) supplemented with 10% (vol/vol) fetal calf serum (Sigma) for
NIH3T3 cells, and fetal bovine serum for 293 cells. The BALB/c mouse mammary
epithelial cell line HC11 (kindly provided by Dr. C. Shermanko; University of Calgary)
and MCF7 cells were maintained in RPMI 1640 medium (Hyclone) containing 10%
(vol/vol) fetal calf serum and supplemented with 5 µg/ml insulin (Sigma), and 10 ng/ml
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EGF (Calbiochem). MCF10A series cell line were maintained in DMEM-F12 media
containing 0.5 ug/ml hydrocortisone, 10 ug/ml insulin, 20ng/ml human EGF and 5%
(vol/vol) horse serum heat inactivated. The MMTV-Myc cell line was derived in the lab
by E. Kirou. Briefly, mammary adenocarcinomas were freshly dissected from
multiparous female mice, then tumor tissue was directly placed in fresh, collagenase
buffer (10 mM Hepes, 2.5% FBS, RPMI 1640 supplemented with Lglutamine). Tissues
were homogenized for 25 Min, and cells were subsequently isolated by multiple
centrifugations. All cell lines were maintained in a media containing 2 mM L-glutamine
(Sigma), penicillin (Invitrogen), and streptomycin (Invitrogen), and were cultured in a
5% CO2 environment.
Plasmid and Mutagenesis Creation of the Myc-Spy1-PCS3 vector was described
previously [14]. Myc-Spy1-TST-PCS3 was created using Quik Change PCR Multi SiteDirected Mutagenesis (SDM) (Stratagene) in 3 sequential steps. An alanine mutation was
created at T15 in Spy1-PCS3 to form Spy1-T15A using primers #A151 5’GAGACACCACCTACTGTCGCTGTTTATGTAAAATCAG-3’

and

#A152

5’-

CTGATTTTACATAAACAGCGACAGTAGGTGGTGTCTC-3’; an alanine mutation
was then introduced at S22 to produce Spy1-T15A-S22A using primers #A139 5’GTTTATGTAAAATCAGGGGCCAA

TAGATCACATCAGC-3’

CTGATGTGATCTATTGGCCCCTGATTTTACATAAAC-3;

and

and
a

#A140
third

5’-

alanine

mutation was introduced at T33 to form Myc-Spy1-TST-PCS3 using primers #A-153 5’CAGCCTAAAAAGCCCATTGCACTGAAGCGTCCTATTTG-3’

and

#A154

5’-

CAAATAGGACGCTTCAGTGCAATGGGCTTTTTAGGCTG-3’. Successful cloning
in all cases was determined by DNA sequencing (Robarts Sequencing Facility; Univ. of
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Western Ontario). Plasmids for FLAG-FOXO1 (9036), HA-Cdk1 (1888), HA-Cdk1
dominant negative (Cdk1-DN) (1889) and the luciferase reporter construct, 3xIRS, which
contains three copies of the FOXO response element in the promoter of the IGFBP1 gene
(13511), were obtained from Addgene. The plasmid for flag-FOXO1 vector harboring an
amino-acid substitution at S249 (FOXO1-A3/S249A ) was kindly provided by Dr H
Huang, University of Minnesota. Luciferase control plasmids were kindly provided by
Dr. B. Vogelstein, John Hopkins university, Baltimore. Ras-V12 was kindly provided by
Dr. S. Lowe, Cold Spring Harbor Laboratory, New York.
Antibodies
Primary antibodies were as follows: Myc (9E10 and C19; Santa Cruz), HA (Y11 and F7;
Santa Cruz), andCdk1 (ab31687; Abcam). . HRP conjugated secondary mouse antibody
(A9917) and rabbit antibody (A0545) were purchased from Sigma.
Transfection
Cells were transfected using polyethylenimine (PEI) branched reagent Sigma (408727),
10 µg of DNA (unless otherwise indicated) was mixed with 50 µL of 150 mM NaCl and
3 µL of 10 mg/ml PEI for 10 Min then added to a 10 cm tissue culture plate. Transfection
media was changed after 8 h for NIH cells and remained overnight for the 293 cells.
Cell Synchronization and Flow Cytometry
Cells were synchronized using double thymidine block; in brief cells were cultured in a
media containing 2 mM thymidine for 16 h released to normal media for 8 h, followed by
a 14 h block in 2 mM thymidine and then released in 70 ng nocadozol. NIH cells were
synchronized by being cultured in a 2% serum containing media for 24 h, followed by
release in standard culture media.
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Flow cytometry analysis; 293 cells were collected at indicated times, washed
twice in PBS, and then either used immediately or frozen for future analysis. Frozen cells
were resuspended at 2 x 106 cells in 1 ml of PBS, fixed by the drop wise addition of an
equal amount of ethanol, and frozen at 80 oC. Within 1 week, fixed frozen cells were
pelleted, washed, and resuspended in 300 µl of PBS. Samples of resuspended cells or
fresh cells were treated with 1 µl of 10 mg/ml stock of DNase free RNase (Sigma) and 50
µl of 500 mg/ml propidium iodide stock solution. A minimum of 300,000 cells were
analyzed per treatment using a Beckman Coulter FC500 (Biology Dept. U of Windsor).
Immunoblotting (IB) and Immunoprecipitation (IP)
Total protein was isolated from cell cultures by harvesting cells and lysing them in 0.1%
NP-40 lysis buffer (5 ml 10% NP-40, 10 ml 1M Tris pH 7.5, 5 ml 0.5M EDTA, 10 ml
5M NaCl up to 500 ml RO water) containing protease inhibitors (10 ȝl/ml PMSF stock
solution 10 mg/ml, 3 ȝl/ml aprotinin stock solution 20 mg/ml, 10 ȝl/ml leupeptin stock
solution 1 mg/ml) for 30 Min on ice. For all cell lysates; Bradford Reagent was used to
determine the concentration of proteins in lysates following the manufacturer’s
instruction (Sigma). Aliquots of lysates containing 20-30 ȝg protein were subjected to
electrophoresis on denaturing SDS-10% polyacrylamide gels and transferred to PVDFPlus 0.45 micron transfer membranes (Osmonics Inc.) for 2 h at 30V using a wet transfer
method. Blots were blocked for 2 h in TBST containing 3% non-fat dry milk (blocker) at
room temperature, primary antibodies were reconstituted in blocker and incubated over
night at 4°C, secondary antibodies were used at a 1:10,000 dilution in blocker for 1 h at
room temperature. Blots were washed three times with TBST following incubation with
both the primary and secondary antibodies. Washes were 6 Min each following the
primary

antibody

and

10

Mineach

following

the

secondary

antibody.
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Chemilumiminescent Peroxidase Substrate was used for visualization following the
manufacturer’s instruction (Pierce). Chemiluminescence was quantified on an Alpha
Innotech HD2 (Fisher) using AlphaEase FC software.
For immunoprecipitation, equal amounts of protein were incubated with primary
antisera as indicated overnight at 4°C, followed by the addition of 10 ul protein A–
Sepharose (Sigma) and incubated at 4°C with gentle rotation for an additional 2 h. These
complexes were then washed 3 times with 0.1% NP-40 lysis buffer and resolved by 10%
SDS-PAGE.
Quantiative/Real-Time Reverse Transcriptase PCR (Q-RT-PCR)
Total RNA was extracted using the RNAeasy Plus Mini Kit (Qiagen) and reverse
transcribed using 200 U Superscript II (Invitrogen), 0.5 g Oligo dT’s and 0.5 g random
nanomers (Sigma) according to the manufacturer instructions. Q-PCR was carried out
using SYBR green detection (Applied Biosystems) with 400 nM of each primer (Table 1;
Suppl. Mat.) and PCR was performed using ABI Prism 7300 thermocycler. Data was
analyzed using ABI 7300 software and represented log10 relative quantification (RQ)
relative to control. Custom primers were designed using Primer Express software
(Applied Biosystems).
Kinase Assays
Cells were transfected with the indicated plasmids, cultured in 10% FBS and lysed in
0.1% NP–40 lysis buffer. 16 h post-transfection IP was carried out as described above and
precipitates washed four times prior to the addition of 50 ȝl of kinase buffer (50 mM
Tris–HCl pH 7.5, 10 mM MgCl2, 1 mM DTT, 20 mM EGTA, 50 mM ATP, 10 mCi of
[Ȗ–32P]ATP) and 74 ȝg/ml H1 histone (Boehringer Mannheim). Reactions were incubated
for 10 min at 30°C, sample buffer was added to stop the reaction and 50 ȝl of each
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sample were analyzed by 10% SDS–PAGE, followed by transferring to PVDF
membrane. The amount of incorporated phosphorylation was visualized using a Cyclone
storage phosphor system and quantified using OptiQuant software (Perkin Elmer,
Biology Department UofW).
Luciferase Assay
Cells were transfected with the appropriate luciferase reporter construct in the presence or
absence of a variety of constructs as indicated in the figures. Cells were harvested 24 h
post-transfection and 50 ul of cell suspension was mixed with 50 ul of with Bright-glo
reagent (E2620; Promega). Luminescence spectra of the samples were measured using a
plate reader (Wallac Victor 1420; PerkinElmer 3TM-1420).
Soft Agar Assay
Two layers of agar/media mixture were plated into 60 mm culture dishes. Briefly
0.6 g of Noble agar (UBS, 9002-18-0) was suspended in 100 ml DI water to yield a 0.6%
bottom agar concentration. This mixture was completely dissolved and then was poured
into two 50 ml tubes, sealed with tape and placed at 40oC for 40 minutes. Simultaneously,
DMEM media enriched with 2X fetal bovine serum was also incubated at 40oC. The
bottom agar layer contained 1.5 ml of 6% agar solution and 1.5 ml of media solution and
was poured and plated. When solidified a top agar layer was prepared containing a 3%
agar solution. Cells (~2.5 x 105) were harvested, counted and added to the top agar +
media mix and then promptly layered onto of the bottom agar layer. Plates are set for 1 h
in the cell culture hood and then incubated at 37oC in 5% CO2 for 12-14 days. Triplicate
transfections for each experiment were observed using light microscopy and pictures
were taken using an Apha Innotech HD2 camera colonies were counted manually under
the light microscope.
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Focus Assay
Low passage cells were grown in 10 cm plates and then transfected with the indicated
constructs using the PEI method described above. Upon reaching confluency media with
reduced serum (2% calf serum) was gently changed every other day for up to two weeks.
The plates were stained with 0.5% crystal violet and colonies were taken using an Apha
Innotech HD2 camera and counted manually.
Fat Pad Transplants
Fat pad transplant assays were conducted using BALB/c mice, which are syngenic for the
HC11 cell line. Mice were maintained following the guidelines of the Canadian Council
on Animal Care and the assay carried out as outlined in U. of Windsor AUPP #06-19 and
previously described [11]. In brief; 5×105 cells were injected into the cleared fat pad of
4th inguinal mammary glands of 22 day old mice and allowed to grow for 1 to 8 weeks.
Tumor presence was monitored weekly by palpitation of the gland. Animals were
sacrificed humanely at the specified time points and glands dissected for analysis.
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Results
Spy1 protein stability is implicated in human breast cancer cell lines
Spy1 protein levels are elevated in human hepatocarcinoma [10]. To determine
whether Spy1 levels may be misregulated at the expression or protein level in subsets of
human breast cancer we utilized a panel of well characterized breast cancer or breast
normal cell lines (Fig. 1 A-B). Samples from non-tumorigenic human breast cell line
(MCF10A) was ran along with cell lines established from tumors driven by MMTV-cMyc (MMTV-Myc), or the MCF10A series human breast cell lines derived from the
MCF10A normal lines above. In addition, the well characterized human breast cancer
lines MCF7, MDA-MB 231, Sum 149 were all tested for Spy1 expression levels using QRT-PCR (Fig. 1A) and western blotting (Fig. 1B)of matched samples. Our data
demonstrates Spy1 protein levels were significantly elevated in the MDA-MB 231 and
MCF10CA1A lines over other breast cancer subtypes. Importantly, when comparing
relative expression at the mRNA and protein levels is it clear that subsets of breast cancer
lines regulate Spy1 protein levels differently than others. This data supports that aberrant
regulation of Spy1 protein levels are implicated in subsets of human breast cancers.
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Figure 1. Spy1 protein levels are elevated in human breast cancer cell lines. (A-B) A
panel of breast cancer cell lines were analyzed for Spy1 protein and RNA. (A) QRT-PCR
analysis for Spy1 RNA for the same breast cancer cell lines.(B). Western blot analysis for
Spy1 protein levels for the indicated cell lines.
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Stable Spy1 protein has oncogenic properties
To test the functional significance of stabilizing Spy1 protein we first performed a
soft agar assay utilizing Spy1 wild-type (Spy1-WT), the non-degradable form of Spy1
(Spy1-TST) along with activated Ras (Ras-V12) as a positive control and empty PCS3 as
a negative control (Fig. 2A). Colonies were formed in the presence of Ras-V12 as well as
Spy1-TST but no colonies were present in the negative control or Spy1-WT.
Quantification over three different transfections demonstrated that Spy1-TST yielded 4
times more colonies than the Spy1-WT counterpart (Fig. 2B). Densitometry analysis of
protein levels of transfected Spy1 normalized using Actin levels shows more than a 2 fold
increase in the overall Spy1 protein levels (Fig. 2C). This is not surprising given that we
are utilizing asynchronous cells and there are multiple mechanisms for regulating Spy1
protein levels [12,13]. Functionally this suggests that Spy1-TST-mediated oncogenic
properties are not explained merely by the accumulation of overall amounts of protein.
To further test this result on the parameters of contact inhibition we performed a foci
formation assay using NIH cell lines (Fig. 2D). Approximately 6-fold more foci were
formed from the Spy1-TST and Ras-V12 expressing cells as compared to foci derived
from the Spy1-WT counterparts, negligible foci were formed in the case of the negative
control cells as well (Fig. 2E). Densitometry of relative protein levels, when normalized
to Actin, demonstrate that Spy1-TST resulted in less than a 1.5 fold increase in overall
protein, further supporting as above that Spy1-TST effects on cell growth properties are
not adequately explained by increases in overall protein levels (Fig. 2F l). To further test
the effects of overall protein concentration on colony formation, a soft agar assay was
performed using increasing concentrations of both Spy1-WT and Spy1-TST (Fig. 2G).
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When transfected with 20-30 ug of DNA, Spy1-WT yielded significant colony growth,
demonstrating that at very high levels the WT protein is capable of exhibiting
transforming properties. However, even when relative protein levels are measured at a
higher level for Spy1-WT (ie. comparing 20 ug of Spy1-WT with 7.5 ug of Spy1-TST;
Fig. 2H; lower panel) Spy1-TST yielded at least 2 fold more colonies. Collectively, this
data supports the hypothesis that threshold levels or stabilization of the Spy1 protein
trigger an oncogenic mechanism that may contribute toward Spy1-mediated
tumorigenesis. The significant increase in colonies seen with the non-degradable Spy1
over Spy1-WT supports that the G2/M degradation mechanism previously described may
provide a protective barrier against this oncogenic pathway.
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Figure2. Spy1 stable protein induces colony formation. HEK 293 cells (A-C) or NIH
3T3 cells (D-G) were transfected with empty myc-tagged vector PCS3 as mock, wildtype myc-Spy1 (Spy1-WT), activated Ras (Ras-V12) and nondegradable myc-Spy1
(Spy1-TST). (A) Soft agar assay was performed and foci were visualized after 14 days
using light microscopy. Representative pictures from one of 3 separate experiments.
Within each experiment assays were seeded in triplicate. (B) Total numbers of foci were
counted over 3 separate plates for each experiment, three different transfections were
performed. The graph is a representative of one of three experiments. Errors bars reflect
SEM between triplicate experiments. t test was performed;** P 0.01. (C) Western blot
analysis was carried out to confirm protein expression for cells transfected in A-B.
Protein levels were quantified using densitometry followed by normalization for Actin
levels. (D) Colony formation assays were conducted and representative views of each
plate recorded using light microscopy. (E) Quantification of the number of colonies over
3 separate plates from one representative experiment of 3. Errors bars reflect SEM
between triplicate experiments. t test was performed;** P 0.01 (F) Western blot analysis
was carried out to confirm protein expression from D-E. Protein levels were quantified
using densitometry followed by normalization for Actin levels. (G) 293 cells were
transfected with different concentrations of both Spy1-WT and Spy1-TST. Soft agar
assay was carried out and plates photographed and quantified on day 14. Foci were
averaged over 3 separate plates for each experiment, three different transfections were
performed. Errors bars reflect SE between triplicate experiments. t test was performed;**
P 0.01,.(H) Representattive western blot analysis of one experiment from cells used in
seeding the soft agar assay described in G upper panel.
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Stable Spy1 protein binds and activates Cdk1 uniquely during mitosis
We previously demonstrated that Spy1-TST remains stabilized at prometaphase
of mitosis upon nocodazole treatment, a time point where Spy1-WT was completely
degraded [12,13]. Hence, we sought to determine whether aberrant degradation of Spy1
will result in elevated Cdk1 activity during mitosis. Cdk1 has been shown to play an
important role in different human cancers, aberrant Cdk1 activation has been described in
number of primary tumors [15] providing a potential novel mechanism for Spy1mediated oncogenic effects.
Reciprocal immunoprecipitation of exogenously expressed Spy1-TST (Fig. 3A;
left panels) or Cdk1 (Fig.l 3A; right panels) demonstrate that these proteins interact in
cells blocked at prometaphase of mitosis using nocodazole. We also examined the
interaction between the endogenous Cdk1 and Spy1-TST (Fig. 3B). This figure
demonstrates that endogenous Cdk1 interacts with Spy1-TST at prometaphase of
mitosis,. To further investigate if Spy1-TST expression leads to unique activation of
Cdk1, cells synchronized with nocodozole overexpressing Spy1-WT or Spy1-TST were
immunoprecipitated with Cdk1 antibody and the lysates were subjected to an in vitro
kinase assay using histone 1 (H1) as a substrate (Fig. 3C). Spy1-TST significantly
increased histone phosphorylation (Fig. 3C; left panels) demonstrating approximately a
3-fold increase over control transfected cells and approximately a 2-fold increase over
Spy1-WT transfected cells (Fig. 3C; right panels).
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Figure 3. Spy1 stable protein binds and activates Cdk1. HEK293 cells were transfected
with Myc-Spy-WT or Myc-Spy1-TST in the presence or absence of HA-Cdk1.(A) cells
were treated with 70 ng Nocodazole for 16 h. Equal amounts of protein were
immunoprecipitated with either Myc antibody (right lanes; left hand panel) or HA
antibody (right lanes; right hand panel). In both cases immunoprecipitation with IgG was
used as a negative control (left hand lanes). Precipitates were analyzed using 10% SDS
PAGE followed by immunoblotting as indicated. Left 3 panels indicate IPs and right
panels represent the lysate loading controls. One representative experiment of 2. (B).
Equal amounts of protein were immunoprecipitated (left panels) with Cdk1 antibody,
analyzed by 10% SDS PAGE followed by immunoblotting Myc antibody (Fig2B; right
panels). Cells transfected as above were lysed and analyzed using 10% SDS PAGE
followed by immunoblotting. (C). Cells were treated with 70 ng nocadazole for 16 h.
Equal amount of protein was immunoprecipitated with Cdk1 antibody and subjected to
H1 phosphorylation assay. Samples were analyzed using 10% SDS PAGE and then
imaged on a Cyclone phosphorimager then the same membrane was probed using Cdk1
antibody and imaged on an Alpha Innotech HD2. Phosphate incorporation was quantified
using OptiQuant software; right panel represents results of one representative experiment
of 3. Errors bars reflect SEM. t test was performed *, P<0.05;**,P<0.01.
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Spy1-TST oncogenic activity is dependent upon activation of Cdk1
Spy1 protein is known to regulate cell cycle progression at least in part through
the direct binding to Cdks [3]. In somatic cells the primary partner for Spy1 appears to be
the G1/S Cdk Cdk2, and Cdk2 activity is essential for overexpressed levels of Spy1to
enhance proliferation [3]. Despite this, Spy1 is capable of also binding and activating
Cdk1 [16]. To determine the role of the Spy1 Cdk effectors on Spy1- mediated
transformation we utilized a mutant form of Spy1-TST where the aspartic acid residue at
position 90 is mutated to a nonpolar alanine group (Spy1-TST/D90A), a modification
previously demonstrated to significantly reduce Spy1-Cdk binding [16]. The Spy1TST/D90A mutation produced significantly fewer colonies in a soft agar assay than
Spy1-TST, being

greater than 5-fold less transforming (Fig. 4A & B). To further

investigate the relative contribution of each kinase individually to this effect, soft agar
assays were performed using Spy1-TST in the presence of either Cdk1-DN or Cdk2-DN
(Fig. 4C). Interestingly, Cdk1-DN reduced colony formation by ~60% with high
statistical significance over 3 separate trials while Cdk2-DN demonstrated reduced
colony numbers but this result was not statistically significant (Fig. 4C & D). This was
not due to inefficient function of the dominant negative construct as the Cdk1-DN
transfection reduced overall Cdk1 kinase activity as efficiently as the Cdk2-DN
transfection (Fig. 4E). Collectively this data supports that the oncogenic function of
Spy1-TST is dependent, at least in part, on the binding and activation of Cdk1.
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Figure 4. Spy1-TST mediated colony formation is Cdk1 dependent. (A) Soft agar assays
of 293 cells transfected with the indicated constructs were imaged 14 days posttransfection using light microscopy and pictures were taken using an Apha Innotech HD2
camera, this is one representative experiment of three. (B) Quantification of colony
number over three separate trasfections. (C) Soft agar assays of 293 cells transfected with
Spy1-TST in the presence or absence of Cdk dominant negative constructs (Cdk1-DN or
Cdk2-DN) are depicted at 14 days post-transfection using light microscopy and pictures
were taken using an Apha Innotech HD2 camera , this is one representative experiment of
three. (D) Quantification of colony number over three separate transfections. Errors bars
reflect SEM. t test was performed *, P<0.05;**,P<0.01.(E) 293 cells were transfected
with Myc-tagged empty vector control (PCS3), Myc-Spy1-TST (Spy1-TST) and
Cdk1/Cdk2 dominant negative (Cdk1/Cdk2-DN). Equal amount of protein was
immunoprecipitated with Cdk1/Cdk2 antibody and subjected to H1 phosphorylation
assay. Samples were analyzed using 10% SDS PAGE and then imaged on a Cyclone
phosphorimager (upper panel) then the same membrane was probed using Cdk1/Cdk2
antibody and imaged on an Alpha Innotech HD2 (lower panel). Phosphate incorporation
was quantified using OptiQuant software; lower graph represents results of one
representative experiment of 2.
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Cdk1 activation by Spy1-TST inhibits the apoptotic mediator FOXO1
Huang and colleagues reported that Cdk1 activation inhibits the transcriptional
and apoptotic activities of the transcription factor FOXO1, thereby potentiating Rasmediated oncogenesis [17]. To investigate the effect of Spy1-TST on FOXO1-induced
apoptosis, 293 cells were transfected with FOXO1 and the effects of FOXO1 mediated
apoptosis were studied in the presence or absence of Spy1-TST and/or variants of Cdk1
(Fig. 5A). As previously reported, FOXO1 induced robust apoptosis when expressed
alone and this effect was diminished with ectopic expression of Cdk1 (Fig. 5A; right top
panel compared to left middle panel). Double transfection with FOXO1 and Spy1-TST
resulted in significant reduction of the FOXO1-induced apoptosis activity (Fig. 5A, left
bottom panel). To test if this reduction was mediated through Cdk1 activation a Cdk2DN was transfected along with Spy1-TST and FOXO1 (Fig. 5A; bottom panel). The
effect of Spy1-TST was indeed reversed by the introduction of the Cdk1- DN, supporting
that Spy1-TST inhibition of FOXO1 is due to Cdk1 activation. To further investigate the
effect of Spy1-TST on FOXO1 transcriptional activity, a series of luciferase assays were
performed (Fig. 5C-E). Ectopic expression of Spy1-TST reduced FOXO1 transcriptional
activity as significant as the expression of Cdk1 (Fig. 5C). To check if this result is due to
Cdk1 phosphorylation of FOXO1 we utilized a mutant of FOXO1 mutant unable to be
phosphorylated by Cdk1, FOXO1-S249A [17,18]. Ectopic transfection of Spy1-TST
with FOXO1-S249A prevented the inhibition of FOXO1 transcription by Cdk1 and by
Spy1-TST (Fig. 5D). Furthermore, Spy1-TST was unable to suppress FOXO1-mediated
transcription in the presence of the dominant negative form of Cdk1, Cdk1-DN (Fig. 5E).
Collectively these data support that the transcription factor FOXO1 is a downstream
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target of the Cdk1/Spy1 complex and represents a potential mechanism of Spy1-TSTmediated oncogenesis.
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Figure 5. Spy1 stable protein inhibits FOXO induced apoptosis through Cdk1 activation.
(A) Flow cytometry profiles of 293 cells transfected with the indicated constructs.
Percentage of cells in each phase of the cell cycle as determined by CPX analysis are
indicated on the histograms. Each profile represents no less than 100,000 cells and is one
representative profile of 3 repeats. (B) Percent of cells from each treatment with DNA
content less than G1 (sub-G1) are graphically presented. Errors bars reflect SE between
different transfections. (C-E) Luciferase reporter activity for FOXO in cells expressing
the indicated constructs. Errors bars reflect SEM. t test was performed *,
P<0.05;**,P<0.01.
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Spy1 stable protein accelerates tumor formation in vivo
Spy1 significantly accelerates tumor formation when HC11 cells overexpressing
Spy1 were injected into cleared fat pad of BALB/c mice [11]. Mammary fat pad
transplants were performed to determine the effect and timing of Spy1-TST in vivo as
compared to the overexpression of Spy1-WT (Fig. 6A-C). The fourth inguinal mammary
glands of 22 day old BALB/c were removed to prevent endogenous stem cells from recolonizing the mammary fat pad. Left cleared fat pads were injected with control Spy1WT-HC11, whereas right cleared fat pads were injected with Spy1-TST-HC11 cells. One
week following transplantation, mice were palpated daily to determine the onset of tumor
growth. Tumor onset occurred significantly more rapidly in the Spy1-TST injected
glands, with 50% of the mice presenting with tumors by day 8 as compared to day 13 in
the Spy1-WT mouse population (Fig. 6A). After 5 weeks post-transplantation, mice were
sacrificed to determine the extensiveness of tumor growth. While 100% of the glands
exhibited invasive tumors at this time the average total area of Spy1-TST tumors was
found to be almost twice that of the Spy1-WT (Fig. 6B). These data support that
stabilization of Spy1 protein promotes the onset and enhances tumor growth over that of
Spy1-WT overexpressing glands.
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Figure 6. Spy1 stable protein accelerates tumorigenesis in vivo. (A) Percent of mice
presenting with palpable tumours from 0-19 days post-transplant. Each data point
represents 4 mice transplanted with cells transfected with the indicated constructs; the
whole experiment was repeated three times using three different transfections. MannWhitney Test was performed (p<0.05). (B) Total tumor area was calculated for both
Spy1–HC11 (Spy1-WT) and Spy1-TST-HC11 (Spy1-TST) transplanted glands. Results
were taken from 45 transplants using cells from 3 separate transfections. Errors bars
reflect SEM between transplants from different transfections.
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Discussion
Our lab and others have shown that Spy1 protein is regulated during the cell
cycle; peaking during G1 and being reduced in G2/M phase of the cell cycle [12,13].
Elevated Spy1 protein levels have been implicated in invasive ductal carcinoma and other
types of cancer and ectopic expression of the protein promotes mammary tumorigenesis
[9-11]. We performed a number of in vitro and in vivo assays to investigate the role of
Spy1 protein stability on tumorigenic properties of the cell. Colony and focus formation
assays utilizing either wild-type Spy1 (Spy1-WT) or a non-degradable mutant of Spy1
(Spy1-TST) demonstrate that the stable form of Spy1 and exceptionally high levels of
Spy1-WT protein, exhibit classical oncogenic properties. Our results support that this is
not simply due to a generalized accumulation of the Spy1 protein in that equalizing
relative protein levels between Spy1-WT and Spy1-TST still results in a several fold
increased transformation response in the non-degradable form of Spy1. In fact, Spy1
accumulation was actually found to occur to a modest level in an asynchronous
population of cells, which may be accounted for by alternative pathways mediating Spy1
degradation as recently demonstrated [13].
What then is mediating the oncogenic properties of the non-degradable form of
Spy1? In mammalian somatic cells Spy1 is known to directly bind and activate Cdk2,
functioning like an atypical cyclin [3]. While Spy1 prefers to bind to the G1/S Cdk in
these cell types it has been demonstrated in that Spy1 can bind to more than one Cdk
partner when overexpressed [19] while its Xenopus counterpart was found to bind and
activate both Cdk1 and Cdk2 [1]. In this report we have demonstrated that when Spy1
protein is stabilized it is capable of binding and activating Cdk1 in cells arrested with
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nocodazole, indicating a prometaphase arrest. This is a stage where Spy1-WT is usually
absent. This activation of Cdk1 appears to play a role in the oncogenic properties of
Spy1. Using colony formation assay and Spy1 mutant that does not bind to Cdk1 and
Cdk1 dominant negative constructs, we have demonstrated that Cdk1 activation is an
important factor in the oncogenic properties of the Spy1 stable mutant.
Recently, Huang and others demonstrated that Cdk1 specifically phosphorylates
the transcriptional factor FOXO1 at serine 249, this phosphorylation has been shown to
inhibit the transcriptional activity of FOXO1 and also was found to counteract FOXO1induced apoptosis [17]. Several reports have shown that Cdk1 plays an important role in
different human cancers. Aberrant Cdk1 profiles have been reported in multiple primary
tumors [20,21]. Cdk1 upregulation was reported in human cancer tissues compared to
normal tissues [20,22]. Moreover, Cdc25C, an upstream activator of Cdk1, was found to
be upregulated exclusively in its active form in some human cancers [23]. Here we show
that the abnormal activation of Cdk1 by Spy1 is mimicking the effect of overexpression
Cdk1 that Huang had shown previously. Our results clearly show that Spy1 activation of
Cdk1 inhibits FOXO1 transcriptional activity and reduces FOXO1-induced apoptosis.
Recent studies have found that overexpression of Spy1 will accelerate the rate of
mammary tumorigenesis in the virgin mammary gland [11]. In this present study, we
have demonstrated, using mammary fat pad experiments, that stabilized levels of Spy1
protein significantly increases the rate of of tumorigenesis in vivo as well as the overal
tumour growth. Within two weeks post-transplantation a significant difference was
detected via palpation for the Spy1-TST injected sides of the BALB/c mice. Differences
in the size and total area of tumours were detected beginning at 5 weeks post-surgery.
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Whereas it is known that Spy1 overexpression can lead to invasive and abnormal
morphogenesis [11], we have seen that Spy1-HC11-TST cells significantly accelerate the
width of tumour growth, leading to the possibility that Spy1 stable cell lines increases the
invasiveness of tumorigenesis in vivo. This interestingly corresponds when we study the
metastatic potential of the cell lines expressing Spy1 protein. Interestingly, Spy1 protein
levels are expressed at considerable higher levels in cell lines known to possess
metastatic potential in vivo while, mRNA levels of the same cell lines were not abrogated
when analysed. This supports the hypotheses that Spy1 protein regulation plays a role in
tumour formation and progression.
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Chapter 4
Direct interactions with p27 and Cdk2 regulate Spy1Induced Mammry Tumorigineses.
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Introduction
Cell cycle regulation is an intricately controlled process that plays a critical role in
all cell fate decisions. The catalytic cyclin dependent kinases (Cdk)s are dependent on the
production and destruction of their regulatory subunits, the Cyclin family of proteins.
Additionally, the Cyclin-Cdk complexes are subsequently regulated by Cdk inhibitors
(CKI). It is crucial that this regulation be tightly controlled to prevent the onset of
tumorigenesis, for which uncontrolled cellular proliferation is a hallmark characteristic.
An atypical ‘cyclin-like’ protein known to play a crucial role in regulating somatic cell
proliferation is a member of the Speedy/RINGO class of proteins Spy1A1, herein
referred to as Spy1 [1,2]. Spy1 is capable of binding to, and activating, both Cdk1 and
Cdk2 leading to increased rates of cell proliferation and inhibition of apoptosis when
overexpressed [1,3,4]. Unlike other Cyclin-like proteins, Spy1 has been shown to directly
bind to the CKI p27 ultimately leading to its degradation [5]. The region regulating
interactions with Cdks are well conserved among the Speedy/RINGO family, being
widely referred to as the S/R Box [6]. In order for the Cyclin-Cdk complex to become
fully activated it must be phosphorylated on a conserved Threonine residue, Thr 160 in
the case of Cdk2, which is located near the T-loop [7]. Additionally, Cdks are inhibited
by the phosphorylation of 2 residues present within the ATP binding region of the Cdk
(Thr 14 and Thr 15 in higher eukaryotes) and activated by dephosporylation of these sites
by the Cdc25 phosphatase family [8]. Interestingly, Spy1 is capable of activating Cdks in
the absence of the activating phosphorylation and dephosphorylation of the
corresponding residues [9]. Hence, offering the possibility that Spy1-bound Cdks can be
activated in circumstances where Cyclin-Cdk complexes would otherwise be inactive.
112

The mammary gland is an extensively characterized model system for studying
normal development as well as the processes involved in the onset and progression of
tumorigenesis, in part because the majority of development occurs postnatally and the
gland is not essential for the viability of the organism [10]. The mammary gland
undergoes multiple rounds of proliferation, differentiation and apoptosis corresponding to
puberty/pregnancy, lactogenesis and involution respectively [10-13]. Entry and exit from
each of these developmental stages is tightly controlled by a number of signaling
pathways responding to alterations in circulating hormones; misregulation of these
carefully orchestrated cues represent potential triggers for mammary tumorigenesis. We
have demonstrated that Spy1 levels are high in epithelial cells during the proliferative
phases of mammary development and are significantly reduced during differentiation
[14]. This follows the same trend as that of the proto-oncogene c-Myc, a gene
overexpressed in approximately 70% of all human breast cancer cases [15,16].
Interestingly, c-Myc is capable of activating Spy1 transcription independent of de novo
protein synthesis and like, c-Myc, Spy1 overexpression in the mouse mammary gland
induces rapid and invasive tumorigenesis [14].
Cell cycle regulators play critical roles in both normal mammary development as
well as in the onset and progression of mammary tumorigenesis. p27 is biphasically
regulated during normal mammary development where levels are high during
differentiation and low during proliferative and apoptotic phases [17]. Additionally, p27
is differentially localized throughout the gland being high within epithelial tissues,
especially in the terminally differentiated layers [17,18]. Low levels of p27 have been
correlated with increased Cdk2-cyclin E activity when a cohort of the breast cancer
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population was studied [18,19]. Hence, p27 and subsequent Cdk2 activity are
differentially regulated throughout mammary development. Importantly, it was found that
elevated Cdk2 kinase activity and decreasing levels of p27 correlate positively with
tumorigenic potential and negatively with patient prognosis [20,21]. Thus, targeting
either p27 or Cdk2 may prove to be a valuable therapeutic approach in treating mammary
tumorigenesis and indeed there are currently a number of Cdk drug inhibitors in various
stages of clinical trials [22].
Herein, we will define the essentiality of the direct interaction between Spy1Cdk2 and Spy1-p27, using mutants of Spy1 unable to interact selectively with either of
theses down stream effectors. We test the essentiality of these interactions on mammary
growth, proliferation and tumorigenesis in vitro and in vivo. Our data demonstrates that
abrogation of direct binding between Spy1 and p27 significantly inhibits degradation of
the CKI and subsequently reduces the proliferative capacity of Spy1 in vitro. In
opposition, abrogated direct binding to Cdk2 demonstrated little effect on Spy1-mediated
proliferation in vitro however data supports that the Spy1-Cdk2 interaction may be
pivotal in how cells elicit checkpoint responses to stress. In vivo we have determined that
preventing Spy1 interactions with both p27 and Cdk2 significantly delayed the onset of
mammary tumorigenesis and reduced overall tumour burden with similar efficiency.
Thus, the direct interaction between Spy1 and key effectors p27 and Cdk2 play a crucial
role in mediating separable aspects effects of Spy1-mediated tumorgenesis in vivo.
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Results
Spy1 protein levels are elevated in human breast cancer tissues
Spy1 has been shown to be highly expressed in an individual SAGE analysis study [23],
protein levels have been implicated as a prognostic marker in hepatocarcinoma [24] and
we have demonstrated regulation at both the expression and protein level in a variety of
breast cancer cell lines (unpublished data). To study the levels of Spy1 protein in specific
forms of human breast cancer, we utilized tissue microarrays (TMAs) consisting of 96
cores from breast cancer patients as well as cores taken from either pair-matched or
normal breast samples. Combining values over 2 separate TMA’s of four different breast
cancer tissues; invasive ductal carcinoma, infiltrated ductal carcinoma, intraductal
carcinoma and invasive lobular carcinoma, show that Spy1 is significantly elevated in all
four types of breast cancer as compared to pair-matched adjacent tissue or a normal tissue
samples (Fig. 1). Overall levels of Spy1 were highest in invasive lobular carcinoma and
the most significant changes in levels were found in intraductal carcinoma. These data
support that aberrant regulation of Spy1 protein levels are implicated in all subsets of
human breast cancers studied.
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Figure 1. Spy1 protein levels are elevated in human breast cancer tissues. TMAs
containing cores from invasive ductal carcinoma (IvDC), infiltrated ductal carcinoma
(IfDC), intraductal carcinoma (IDC) and invasive lobular carcinoma (ILC) as well as
pair-matched normal (PM-N) or cancer-free patients (CF-N) were analyzed for Spy1
expression. The Spy1 signal intensity was normalized to nuclear stain (TOTO-3/PI)
signal. Patient numbers are indicated below the sample (N). Data shown is mean ±s.d.
Student’s t-test was performed *, P<0.05;**,P<0.01.
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Determination of the p27 binding region within Spy1
Using a panel of Spy1 deletion mutants previously described [25] we began to narrow
down the region within the Spy1 protein that was necessary for p27 binding. Previously,
it was determined that truncation of Spy1 at aa215 was able to bind to p27 while
truncation at aa160 was not able to bind to p27, demonstrating that the 55aa difference
between these constructs represented a sequence essential for binding to p27 [5] (Fig. 2A;
indicated beneath panel). We first determined whether any our panel of Spy1 deletion
mutants would result in abrogation of binding to p27. 293 cells were transfected with
wild-type Spy1 (WT) or versions of the Spy1 protein harboring the specified deletions
(DMA-DMZ)

(Fig.

2B). Cells were lysed

and

equal

amounts of

protein

immunoprecipitated with Myc antibody and analyzed by western blot. We determined
that deletion of aa145-239 (DMG) was essential for the binding between Spy1 and
p27,confirming previous reported results [5]. While there is a considerable variety in the
recognition motifs for p27 binding partners, it has been noted that p27 binding favors
positively charged amino acids on the binding partner [26]. Alignment of the determined
p27-binding region within Spy1 sequences from a number of different organisms noted a
region of high similarity containing a string of 4 highly conserved positive amino acids
(Fig. 2C). Hence, we generated a mutant of Spy1 containing alanine substitutions for
arginines 170 and 174 (Spy1-R170) as well as a mutant containing alanine substitutions
for arginines 179 and 180 (Spy1-R179) (Fig. 2D).
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Figure 2. Generation of Spy1 – p27 binding mutants. (A) A schematic diagram of the
Spy1 deletion mutants used for screening. Previously defined [5] truncation of Spy1
which retained p27 binding (aa215; depicted by dotted line below), or lost p27 binding
(aa160; depicted by solid line below). (B) 293 cells were transfected with Myc-Spy1PCS3 (WT) or the different deletion mutants DMA-DMZ depicted above in the presence
of HA-tagged p27 (HA-p27). Transfected cells were treated with MG132 (10µM) for 14
hrs prior to harvest, lysates were immunoprecipitated with Myc antibody and
immunoblotted with HA antibody (upper panel) and Myc antibody (lower panel). This is
one representative experiment of 3. (C) Alignment of the amino acid sequence within a
conserved region of DMG from several species. Conserved positively charged residues to
be mutated are noted with a box. Amino acid #s are indicated after the species in
brackets. (D) Region G of Spy1 depicting the Arginine. (R) residues which were mutated
to Alanine (A) to create Spy1-R170 and Spy1-R179 mutations.
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Spy1-R170 and -179 do not bind to p27
To test the necessity of these conserved arginine residues for binding to p27, Myc-tagged
Spy1-WT, Spy1-R170, or Spy1-R179 were transfected in combinations with HA-tagged
p27 in the presence of MG132 (Fig. 3A). Immunoprecipitation/immunoblotting studies
demonstrate that Spy1-R170 and Spy1-R179 mutants both reduce binding to p27 as
compared to Spy1-WT binding (Fig. 3A). Reciprocally, immunoprecipitation using Myc
antibody isolated p27 when Spy1-WT was overexpressed but not the mutant Spy1
constructs (Fig. 3B). Cdk2 continued to bind to Spy1 in the presence of both mutations
(Fig. 3B). We also examined the interaction between the endogenous p27 and either
Spy1-WT or Spy1-mutants. Following immunoprecipitation for the Myc-tagged Spy1
proteins, endogenous p27 protein was detected as part of a complex with Spy1-WT but
not with either of the Spy1 non-binding mutants (Fig. 3C). Collectively, these results
demonstrate that mutation of Spy1 at either arginines 170/174 or 179/180 abrogates
binding interactions with the CKI p27. These will provide a valuable tool in assessing the
specific role for Spy1-p27 interactions in functional experiments.
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Figure 3. R170 and R179 mutants of Spy1 abrogate binding to p27. 293 cells were
transfected with constructs indicated above the panels and treated with 10µM MG132 for
14 h. prior to lysis. Equal amounts of protein were immunoprecipitated followed by
immunoblotting as indicated below each panel (upper panels). For each experiment cell
lysates were also ran and immunoblotted to demonstrate transfection efficiencies (lower
panels). (A) Overexpression of all constructs and immunoprecipitation for HA-tagged
p27. One representative experiment of 3. (B) Overexpression of all constructs and
immunoprecipitation for Myc-tagged Spy1 constructs. One representative experiment of
3. (C) Transfection of Spy1-WT or mutant constructs and analysis using endogenous p27.
Cells were maintained in 2% serum containing media for 14 h. following transfection to
elevate endogenous p27 levels. One representative experiment of 2.
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Effect of Spy1 mutants on p27 degradation
Direct binding of Spy1 protein to p27 enhances p27 degradation and subsequently
activates Cdk2 kinase activity [2,5]. Importantly, Spy1 also directly binds to Cdk2 to
activate kinase activity and it is known that Cdk2 phosphorylation of p27 on T87
promotes p27 degradation [27] Therefore, to determine whether the direct binding of
Spy1 to p27 and/or Cdk2 is critical for Spy1-mediated degradation of p27 we utilized 293
cells transfected with either the Spy1-p27 non-binding mutants (Spy1-R170 and Spy1R179) or the Spy1 mutant unable to interact with Cdk2 (Spy1-D90) and the lysates were
monitored by western blot (Fig. 4A; left panel). Results from 3 separate experiments
were quantified by densitometry and differences in the protein levels of p27 were
analyzed for statistical significance (Fig. 4A; right panel). Cells transfected with Spy1WT and Spy1-D90 resulted in a significant reduction in overall p27 protein levels,
quantified as less than half that seen in cells overexpressing an empty vector control, or
the Spy1-p27 non binding mutants (Fig. 4A). To further confirm these results we used
radioactive sulfur (S35) incorporation in a pulse chase assay, immunoprecipitated for p27,
followed by SDS-page (Fig. 4B; left panel) and phosphor-image analysis to determine
relative stability of p27 protein levels over 3 separate experiments (Fig. 4B; right panel).
IgG was used as a control for the immunoprecipitation and lysates used for control over
transfections (Fig. 4B; left bottom panels). Quantification of this data demonstrates that
Spy1-WT and Spy1-D90 significantly reduced the stability of p27 protein levels over the
empty vector (PCS3) control, however the Spy1-R170/R179 mutants were unable to
significantly impact p27 turnover, hence demonstrating that the direct binding between
Spy1 and p27 is essential for Spy1 effects on p27 protein turnover.
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To examine the effect of Spy1 mutants on cell proliferation, cells were transfected
with the indicated constructs and cell number after 24 hr. was assessed by trypan blue
exclusion (Fig. 4C). Cells transfected with the Spy1 mutants unable to interact with p27
showed a significant decrease in the total cell number as compared to Spy1-WT, being
comparable to that of the empty vector control (PCS3). Importantly, the Spy1 mutant
unable to interact with Cdk2 (Spy1-D90) resulted in a significant increase in the total
number of cells over the empty vector control, with numbers comparable to that of Spy1WT. Collectively, these results demonstrate that abrogating the direct binding between
Spy1 and p27 is detrimental for Spy1-mediated proliferation while abrogating the direct
binding between Spy1 and Cdk2 is not.
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Figure 4. R170 and R179 mutants inhibit p27 down regulation. 293 cells were
transfected with HA-tagged p27 in the presence or absence of Myc-tagged empty–vector
(PCS3), Spy1-WT, Spy1-R170, Spy1-R179 or Spy1-D90. (A) Lysates were
immunoblotted with HA (upper panel), Spy1 (middle panel) and Actin (lower panel)
antibodies. Left panel reveals one representative blot of 3. Right panel reflects
densitometry of p27 levels equalized with actin over 3 separate experiments. Error bars
represent SEM. *= P<0.05

(B) Pulse chase assay was conducted, followed by

immunoprecipitation for HA-tagged p27 and S35 incorporation measured by phosphor
image analysis (image; upper left panel). Immunoblot using IGg antibody was used as a
control (lower left panel). Right panel represents quantification using OptiQuant
software. This is one representative experiment of 3, error bars represent SEM, *=
P<0.05 (C) 30 h post-transfection cells were collected and counted using trypan blue
exclusion. Error bars represent SEM. *= P<0.05 This is one representative experiment of
3
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Spy1 direct binding to both p27 and Cdk2 are important for Spy1-mediated tumorigenesis
in vivo
It has previously been shown that overexpression of Spy1 in vivo leads to accelerated
rates of mammary tumorigenesis [14]. To determine if this is dependent on Spy1’s
interaction with either Cdk2 or p27, fat pad transplantation was performed on the cleared
inguinal mammary gland of Balb/C mice using wild-type Spy1 (Spy1-WT) expression on
one side of the mouse and Spy1 mutants defective for either Cdk2 binding (Spy1-D90) or
p27 binding (Spy1-R170) on the opposite side. One week following surgery,
approximately 70% of all Spy1-WT glands had visible tumors while only 15% of all
Spy1-D90 glands and 10% of all Spy1-R170 glands had visible tumors (Fig. 5A). At day
21 post-transplant ~70% of the Spy1-D90 glands had detectible tumors, similar to that of
Spy1-WT glands while the Spy1-R170 glands were still ~60% tumor-free. However, by
day 28 post-transplant 100% of Spy1-WT glands had detectable tumours, only 10%
remained tumor-free for Spy1-D90 and ~20% were tumor-free for the Spy1-R170
mutant. Mice were humanely sacrificed at day 28 post-surgery due to the size and
invasiveness of the Spy1-WT glands and glands were removed and studied. There were
dramatic differences in the overall tumor size observed with Spy1-WT glands being
much larger and more invasive than both the Spy1-D90 and Spy1-R170 tumors (Fig. 5B).
These data indicate that Spy1 direct interactions with both p27 and Cdk2 are important
for Spy1-mediated tumorigenesis in vivo. It further suggests that inhibition of both of
these functional pathways is required to significantly reduce tumorigenic effects over
time.
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Figure5. Spy1 tumorogenic activities are p27 and Cdk2 dependent.
Cleared mammary fat pads were transplanted with cells expressing Spy1-WT (WT) on
the left and either Spy1-R170 (R170) or Spy1-D90 (D90) on the right. (A) Graphic
depiction of the percent of mice remaining free from palpable tumours at time points
following transplantation. Treatments occurred in groups of 3 using 3 separate colonies
of infected cells.. Mann-Whitney Test was performed (p<0.05). (B) Mice were humanely
sacrificed at the indicated time points and glands showing visible tumors were isolated
and measurements of height, length and width of the tumors were recorded. Total average
tumour area over 45 mice transplanted with either R170 or D90 (right gland) and Spy1WT (left gland) from three separate infections are depicted.*,P<0.05.
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Materials and methods
Cell culture
Mouse embryonic fibroblast cell line, NIH3T3 (NIH) and human embryonic kidney cell
line, HEK293 (293) were both purchased from ATCC and maintained in DMEM medium
(Sigma) supplemented with 10% (vol/vol) fetal calf serum (Sigma; NIH) or fetal bovine
serum (Hyclone). HC11, a non-immortalized BALB/c mouse mammary epithelial cell
line (provided by Dr. C. Shermanko; University of Calgary) were maintained in RPMI
1640 medium (Hyclone) containing 10% (vol/vol) fetal calf serum (Sigma),
supplemented with 5 µg/ml insulin (Sigma), and 10 ng/ml EGF (Calbiochem). All cell
lines were maintained in a media containing 2mM L-glutamine (Sigma), penicillin
(Invitrogen), and streptomycin (Invitrogen), and were cultured in a 5% CO2 environment.
Plasmid and mutagenesis
Creation of Myc-Spy1 in PCS3 was described previously [1]. Flag-Spy1-PEIZ was
generated by moving Flag-Spy1 from Spy1-PJT0013 previously described [2] through
EcoR1 and Xba1 restriction sites into the lentivirus vector PEIZ (provided by Dr. B.
Welm, University of Utah). Spy1-D90 and Spy1-R170 were created in Myc-Spy1-PCS3
using Quik Change PCR Multi Site-Directed Mutagenesis (SDM). Myc-Spy1-R170PCS3

mutation

was

made

using

primers

#

A315

5'-

GTTAAGGGACCAGCTCTGGGATGCAATTGACTATGCGGCTATTGTAAGCAGG3' and # A316 5'CCTGCTTACAATAGCCGCATAGTCAATTGCATCCCAGAGCTGGTCCCTTAAC-3'
;Myc-Spy1-D90-PCS3

was

made

using

primers

GATTTCTTGTGGATGGCATGCTGCTGTAAAATTGC-3'

#A123
and

#A124

GTTAAGGGACCACTGGGATGSAAGACTATGCGGCTATTGTAAGCAGG

5'5'3',
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Spy1-R170-PIEZ lentivirus plasmid was created by engineering an EcoR1 site upstream
Spy1

in

Myc-Spy1-PCS3

using

primers

#A532

5’-

CTTGATTTAGGTGACACTATAGAATTCAAGCTTGTTCTTTTTG-3’ and #A533 5’CAAAAAGAACAAGTAGCTTGAATTCTATAGTGTCACCTAAATCAAG-3’. MycSpy1-R170 was moved to PIEZ lentivirus vector via the EcoR1 and XbaI sites.
Successful cloning in all cases was determined by DNA sequencing (Robarts Sequencing
Facility; Univ. of Western Ontario).
Fat pad transplants
BALB/c mice were maintained following the Canadian Council on Animal Care
guidelines at the University of Windsor (protocol #06-19). HC11 cells infected and
selected for the relevant lentiviral constructs were injected into the cleared fat pad of the
fourth mammary glands in 22-day old mice (250,000 cells per gland) as previously
described [14]. Tumor incidence was monitored every 2 to 4 days beginning one week
after surgery by palpitation of the gland. Glands were allowed to grow for 2 to 4 weeks
following

surgery.

Collected

glands

were

either

paraffin

embedded

for

immunohistochemistry or flash frozen for protein, genomic or mRNA analysis.
Quantitative reverse transcriptase PCR (Q-RT-PCR)
Total RNA was extracted using the RNAeasy Plus Mini Kit (Qiagen) and reverse
transcribed using 200 U Superscript II (Invitrogen), 0.5g Oligo dT’s and 0.5 g random
nanomers (Sigma) according to the manufacturer instructions. Q-PCR was carried out
using SYBR green detection (Applied Biosystems) with 400 nM of each primer (Table 1;
Suppl. Mat.) and PCR was performed using ABI Prism 7300 thermocycler. Data was
analyzed using ABI 7300 software and represented log10 relative quantification (RQ)
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relative to control. Custom primers were designed using Primer Express software
(Applied Biosystems).
Immunoblotting
Cells were harvested and lysed in 0.1% NP-40 lysis buffer (5 ml 10% NP-40, 10 ml 1M
Tris pH 7.5, 5 ml 0.5M EDTA, 10 ml 5M NaCl up to 500 ml RO water) containing
protease inhibitors (10 ȝl/ml PMSF stock solution 10 mg/ml, 3 ȝl/ml aprotinin stock
solution 20 mg/ml, 10 ȝl/ml leupeptin stock solution 1 mg/ml) for 30 Min on ice.
Bradford Reagent was used to determine the protein concentration following the
manufacturer’s instruction (Sigma). Aliquots of lysates containing 20-30 ȝg protein were
subjected to electrophoresis on denaturing SDS-10% polyacrylamide gels and transferred
to PVDF-Plus 0.45 micron transfer membranes (Osmonics Inc.) for 2 h at 30V using a
wet transfer method. Blots were blocked for 2 h in TBST containing 3% non-fat dry milk
(blocker) at room temperature, primary antibodies were reconstituted in blocker and
incubated over night at 4°C, secondary antibodies were used at a 1:10,000 dilution in
blocker for 1 h at room temperature. Blots were washed three times with TBST following
incubation with both the primary and secondary antibodies. Washes were 6 Min each
following the primary antibody and 10 Min each following the secondary antibody.
Chemilumiminescent Peroxidase Substrate was used for visualization following the
manufacturer’s instruction (Pierce). Chemiluminescence was quantified on an Alpha
Innotech HD2 (Fisher) using AlphaEase FC software.
For immunoprecipitation, equal amounts of protein were incubated with primary
antisera as indicated overnight at 4°C, followed by the addition of 10 ul protein A–
Sepharose (Sigma) and incubated at 4°C with gentle rotation for an additional 2 h. These
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complexes were then washed three times with 0.1% NP-40 lysis buffer and resolved by
10% SDS-PAGE.
Transfections and infections
Cells were transfected overnight using polyethylenimine (PEI) branched reagent Sigma
(408727), 10 µg of DNA was mixed with 50 µL of 150 mM NaCl and 3 µL of 10 mg/ml
PEI for 10 Min then added to a 10 cm tissue culture plate.
Lentiviral infections were carried out using a modified protocol from Welm et. al
[28]. In brief; PEI transfection of Lenti-XTM 293 producer cell lines (Cat. No. 632180,
Clontech, Mountain View, CA, USA) was conducted as described above, 16 h posttransfection, media containing viral particles was concentrated, tittered and stored at 80°C (detailed protocol; Appendix 1). Cells were screened for ZS-Green using flow
cytometry. HC11 infections were optimized using 2x105 cells/well; 6-well plate to
determine the multiplicity of infection (MOI), an MOI of 10 was determined for HC11.
Briefly, HC11 were seeded with media lacking antibiotics for 18 h the media removed
and transfection media lacking antibiotics and serum is added. Virus particles were added
in final concentrations of 8*105 TU(transfection unit = MOI * cell number), and
polybrene added to a final concentration of 10 ug/ml and incubated for 4 h. After 4 h
media was changed to media lacking antibiotic only.
Antibodies
The generation of Spy1 antibody was previously described [1]. Myc antibodies both
mouse (9E10) and Myc rabbit (C19), the HA probes (Y11 and F7) and p27 (F8) were
purchased from Santa Cruz. Actin antibody (MAB150R) was purchased from
Calbiochem. HRP conjugated secondary mouse antibody (A9917) and rabbit antibody
(A0545) were purchased from Sigma.
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Pulse chase
16 h post-transfection with indicated constructs cells, serum free media was replaced with
Cys-Met free media (D0422; Sigma) supplemented with dialyzed FBS (F0392; Sigma)
for 1 h. S35 was added to a final concentration of 500 µCi for 4 h. followed by 4 washes
with 1X PBS and supplementation with growth media containing 2 mM Cys-Met. Cells
were lysed at indicated time points, ran on an SDS-page gel. Incorporated sulfur was
visualized using a Cyclone storage phosphor system and quantified using OptiQuant
software (Perkin Elmer, Biology Department UofW).
Tissue microarray (TMA) analysis
Paraffin embedded TMA slides consisting of 165 tissue cores in total were purchased
from U.S. Biomax (cat # BR721 and BR962). Slides were deparaffinized in xylene and
decreasing percentages of ethanol according to the manufacturer’s instructions. Antigen
retrieval was performed at 95oC in citrate buffer (1mM EDTA, pH 8.0 or 0.01M sodium
citrate buffer, pH 6.0). Slides were washed in 1x PBS and subjected to
immunohistochemistry. Nuclei were counterstained with TOTO-3 (T-3600 Molecular
Probes). The fluorescent signal was detected and quantified by ScanArray Express
(Perkin Elmer Inc.). Spy1 signal intensity was normalized to nuclear stain signal.
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Discussion
Spy1 is an atypical Cdk activator known to increase cell proliferation and inhibit
apoptosis when overexpressed in mammalian cells [1]. In addition to directly binding
and activating Cdks,. in vitro and in vivo experiments demonstrate that Spy1 directly
binds and co-localizes with nuclear forms of with p27, functioning to override p27mediated cell cycle inhibition [2]. Like Cyclin E-Cdk2, Spy1 overexpression is also
associated with an increase in phosphorylation of p27 at T187 leading to its proteasomal
degradation and enhanced cell cycle progression [5]. Whether the effects on p27
degradation are mediated through the direct binding of Spy1 to Cdk2 or p27 was not yey
resolved. To address this question, we utilized a Cdk2 binding mutant (Spy1-D90) that
has been previously described [6], as well as creating a p27 non-binding mutant (Spy1R170) in assays to assess Sp1 effects on p27 turnover. In addition we determined the
effects of these specific Spy1 binding mutants on cell proliferation. We determined that
direct binding of Spy1 to p27 was required to promote p27 degradation, as well as Spy1mediated proliferation. We also demonstrated that Spy1 direct binding to Cdk2 is
dispensable for Spy1 mediated degradation of p27. Surprisingly, Spy1 direct binding to
Cdk2 was also dispensable for Spy1-mediated proliferation. This could be attributed
redundancy, it is known that Spy1 is capable of binding to Cdk1 when its overexpressed
[29] and Cdk1-Cyclin E has the ability to regulate G1/S [30]. In addition to enhancing
cell proliferation, Spy1 plays a role in increasing cell viability during cellular responses
to DNA damage [3],It has been shown that these effects are drivin by the direct binding
and activation of Cdk2 by Spy1 [4]. Collectively, these data highlight the significance of
Spy1 binding to p27 and Cdk2 for Spy1 mediated cell proliferation and apoptosis,
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suggesting that these cellular phenomena are regulated by Spy1 via two separable
pathways.
Role of Spy1-p27 binding in tumorigenesis
Elevated expression of Spy1 has been implicated in one SAGE analysis study of
invasive ductal carcinoma of the breast and elevated protein levels implicated in
hepatocarcinoma [23,24]. Our lab has demonstrated that overexpression of Spy1
accelerates the rate of mammary tumorigenesis in the virgin mammary gland [14]. In this
present study, we show that abrogating direct interactions between Spy1 and either p27 or
Cdk2 significantly decreases the rate of tumorigenesis and overall tumour size in vivo.
Low levels of p27 protein has been implicated in many human cancers including that of
the breast [31]. Lung cancer is associated with one of the highest mortality rate of all
forms of cancer, many studies have demonstrated that the loss of p27 is associated with
increased tumor size, poor prognosis, high tumor grade and poor patient outcome [31]. In
addition, constitutive activation of Cdk2 results in mammary gland hyperplasia, fibrosis,
and mammary tumors in MMTV–cyclin D1–Cdk2 derived cell line [32]. Our results
show the significance of Spy1 binding to both p27 and Cdk2 in driving the tumorogenic
activities of Spy1.
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Chapter 5
General Discussion
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In this work I endeavored to shed light on the role of a novel cell cycle
regulator, Spy1, in the normal cell cycle as well as its role in tumor initiation and
progression. Spy1 protein is a cyclin-like protein which exhibits no amino acid sequence
homology to cyclins but has the ability to bind and activate Cdk1 and Cdk2 independent
of cyclin binding [1].
It is well established that misregulation of cell cycle regulators such as Cdks, CkIs
and cyclins are linked with oncogenesis. This abrogated regulation results in the inability
to properly respond to cellular stress and DNA damage signals during specific
checkpoints designed to halt the cell in such circumstances. Spy1 is not only found to
bind and activate Cdks in normal cell cycle conditions, it is also known found to override
DNA damage by decreasing cellular sensitivity to apoptotic signals [2]. As such, losing
control of crucial regulator like Spy1 is a great danger for normal cell cycle integrity. On
the other hand, cell cycle regulators, including Spy1, do not perform in isolation; instead,
they are active via multiple interactions that form an intercalating surveillance network to
ensure proper cell cycle progression. Therefore, understanding how Spy1 is synthesized
and degraded is essential in resolving how it contributes to normal and abnormal cellular
processes.
Breast and cervical cancers are the most common malignancies in women
worldwide. Uncontrolled cell proliferation, which is associated with the loss of the proper
cell cycle control, is a prominent feature in these cancers [3]. The sequential progression
through the cell cycle depends on regulating the abundance of several proteins through
ubiquitin-mediated proteolysis. Degradation is a precisely timed and specific event (see
Chapter 1 for more details). Cyclin E deregulation impairs progression through S phase
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[4], while cyclin B1 overexpression correlates to aneuploidy and high proliferation in
human mammary carcinomas [5]. To date two reports have discussed the mechanism
regulating Spy1 protein levels in mammalian cells [6,7]. Chapter 2 of this work was the
first to describe a mechanism regulating Spy1 turnover in a mammalian system, in
addition to exploring the degradation mechanism of Spy1 and mapping important
residues on the protein crucial for degradation, we were able to prove that Spy1
misregulation has an impact on the cell cycle, like other core cyclins. Our data revealed
that stabilization of Spy1 protein levels enhances cell proliferation over the wild-type
protein. The second report that came shortly after our work described the same cyclic
profile of Spy1, as well as further describing an alternative degradation mechanism that
involves the E3 ligase SCFSkp2 [6]. The fact that these two reports outlined two different
degradation mechanisms of Spy1 stresses the importance of tight regulation of Spy1
protein. It is well known that most cell cycle regulators, especially those regulated by the
ligase SCFSkp2, have multiple degradation mechanisms involving different E3 ligases [8].
Based on our data we carried on to see if this stable form of Spy1 is capable of
initiating tumors or has any oncogenic activities. Performing different colony formation
assays we were able to show that the stable form of Spy1 has oncogenic activities and
was able to accelerate tumor formation in Balb/c mouse model. These results, along with
work from our lab demonstrating the role of wild type protein in tumor formation, clearly
highlight the importance of Spy1 protein in cancer development and progression [9]. The
onset of Spy1-induced tumor formation described in this work was considerably more
rapid than that seen in Golipour et al. [9]. This difference could be attributed to the
differences in gene delivery mechanisms used; Golipour et al. utilized a retroviral
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infection of a cell population cultured over a long period of time, whereas this work
utilized lentiviral infections to generate 3 separate populations of infected cells grown
over limited number of divisions. The switch in theses systems was made because the
retrovirus infections were not found to maintain stable overexpression, while it appears
from this data that the lentiviral infections are much more efficient in this regard.
Although this work focuses on one aspect of Spy1 regulation, we can not neglect a very
important dimension of Spy1 regulation and its involvement in cancer development.
Transcriptional regulation of Spy1 has been studied previously in our lab, Golipour et al.,
have found that Spy1 is a direct downstream target of the transcriptional factor c-Myc
[9]. Moreover, Spy1 protein and mRNA levels are uniquely elevated in tumor tissues
drivin by the c-Myc oncogene as compared to normal mammary gland tissues. The
importance of these results comes from the fact that c-Myc is overexpressed in about
70% of breast cancer cases [10]. It is very clear that aberrant Spy1 protein levels are
implicated in cancer development and progression, it is possible that transcriptional up
regulation can be attributed to c-Myc-mediated tumorgenesis, our work also demonstrates
that Spy1 protein stability needs to be studied in more depth to resolve how this protein is
regulated an all forms of human cancer.
Cell cycle regulators do not work alone, Spy1 can directly bind and activate Cdk2
and Spy1 also directly interacts with p27, enhancing its degradation and overriding a p27induced cell cycle arrest [11,12]. Considering the role of p27 in tumorgenesis (chapter 1
for review), elevated levels of Spy1 may result in the degradation of this crucial cell cycle
inhibitor, thus accelerating the onset of tumorgenesis. While the proliferative effect of
Spy1 depends on the presence of endogenous p27 in mouse embryonic fibroblasts, Spy1
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is still capable of binding Cdk2 in p27 null cells, suggesting that Spy1 has independent
roles represented by direct interactions with both Cdk2 and p27 [12]. To address the
importance of each of these interactions individually on tumor formation and
development, I have constructed a p27 binding mutant (R170A) and used a previously
described Cdk2 mutant (D90A) [13]. Utilizing these mutants in a Balb/c mouse model we
have demonstrated a significant reduction in tumorogenic properties, including tumor
onset in vivo compared to wild-type Spy1. This delay in tumor formation highlights the
importance of Spy1 binding to both Cdk2 and p27, the fact that tumors still formed in
these mutations necessitate the need to develop a vector inhibiting interaction with both
p27 and Cdk2. It is possible that there are yet other important Spy1 effectors which
remain to be elucidated but represent important mediators in mammary tumorgenesis.
Work from our lab implicates Spy1 in the Wnt/β-Catenin pathway. Despite its numerous
functions, β-Catenin plays a role in cell adhesion and invasion is considered one of the
most important regarding its contribution to tumorgenesis [14] Our data shows that Spy1
interacts with mediators of β-Catenin signaling and stability, Axin and LRP6. Axin is an
essential scaffolding protein in the Wnt pathway which appears to play a role in both the
degradation and stabilization/activation of β-Catenin [15,16]. LRP6 is a membrane bound
receptor which forms a complex with a number of other proteins, including Axin, to
recruit β-Catenin to the membrane and stimulate signaling [15,17]. These data may add
another dimension to Spy1 role in tumorgenesis and support the idea that it is not only
one or two interactions that derives the functionality of Spy1, it is rather an intercalated
cycle of interactions that they have to be addressed independently and in combinations in
primary cell lines and eventually in mouse models. In addition, it is essential to test this
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data using primary cells since the HC11 cells are immortalized have a mutated form p53
and can form tumors by them selves after prolonged time [9]. Hence, whether Spy1 is
acting to promote tumorgenesis only, or Spy1 may initiate tumorgenesis is not yet
resolved.
Collectively our data supports that Spy1 interactions with p27 are essential in
regulating Spy1 proliferative-functions in mammary tumorgenesis and that interactions
with Cdk2 override normal protective cellular barriers, abrogating both interactions is an
essential next step as a proof of principal for testing Spy1 as a putative therapeutic target.
To address this conclusively, wild-type Spy1 and mutated forms os Spy1 need to be
tested using primary cell lines and eventually genetic mouse models.
Perspectives and Future Directions
To clearly understand the development and progression of cancerous cells it is
essential that we elucidate the mechanisms and interactions of normal regulators of the
cell cycle. Spy1, a cell cycle protein elevated in different kinds of cancers including
breast and brain, is tightly regulated during the cell cycle and that elevated levels of Spy1
was shown to promote tumor formation in mammary cells. In this body of work we were
able to elucidate key molecular mechanism mediating Spy1 degradation during the cell
cycle as well as to demonstrate that Spy1 protein regulation may be an important
mediator of tumorgenesis. Further more, we addressed the roles of two downstream
effectors of Spy1; Cdk2 andp27, Spy1-mediated tumor formation as well as mammary
proliferation and differentiation. Although we have seen some delay in tumor formation,
the need of Spy1-p27-Cdk2 double binding mutant is an important next step for this
project. In addition, moving these experiments to include primary cell lines or genetic
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models should be the destination for this follow up. The implications of transcriptional
regulators such as c-Myc in Spy1 mediated tumorgenesis remain to be resolved.
Determination of how Spy1 is differently regulated among tumor types is also an
important future direction.
This work is an important first step in determining how Spy1 is regulated in normal
cells, and how this is differs in specific forms of cancer. Importantly, these studies are the
first to begin to resolve the involvement of key Spy1 effectors in Spy1-medaited
tumorgenesis. This work may provide essential information for the development of future
therapeutics for breast cancer and other forms of disease.
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